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Abstract 
Derek A Holmes 
FoxP3 modulation of HIV-1 Replication and T cell activation 
(Under the direction of Dr. Lishan Su) 
 Regulatory T cells (Treg) are defined as the population of CD4+CD25+ that express 
the forkhead transcription factor family member FoxP3.  Treg cells are characterized by the 
inability to produce IL-2 upon stimulation, defects in in vitro proliferation, and the ability to 
suppress effector T cell (Teff) activation.  FoxP3 plays a crucial role in Treg function and is 
thought to be a factor required for the development and maintenance of Tregs.  We first set 
out to describe the role of FoxP3 in the regulation of HIV LTR activation in Treg cells.  Upon 
primary Treg infection with HIV-1 NL4-luciferase reporter virus, we observed increased 
transcription of the LTR.  Similarly, primary T cells or Jurkat T cells transduced with 
retrovirus expressing Foxp3 showed a similar enhancement of HIV-1 LTR.  We demonstrate 
that Foxp3 enhancement of LTR requires intact NF-κB binding sites, and FoxP3 expression is 
associated with increased binding of NF-κB at the core enhancer of HIV-1 LTR and 
differential histone acetylation of the LTR and IL-2 promoters. 
 We demonstrate that FoxP3 expression in Jurkat T cells and primary Tregs inhibits 
global HDAC activity.  Specifically, Foxp3 inhibits HDAC1 activity and this function requires 
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the proline-rich domain.  We show that FoxP3 is present in a large molecular weight 
complex with HDAC1, and interacts with HDAC1 in T cells.  A point mutation in the forkhead 
domain that inhibits Foxp3 function in Tregs in vivo is unable to associate with and inhibit 
HDAC1 activity, suggesting the importance of FoxP3/HDAC1 interaction for HDAC1 
inhibition.  Finally, we demonstrate knockdown of HDAC1 inhibits FoxP3 regulation of IL-2 
expression and HIV-1 LTR activity in T cells. 
 Lastly, we report that FoxP3 interacts with the ATPase nucleosome remodeler Mi-2β 
in T cells.  This interaction requires the zinc-finger domain, and FoxP3 expression is 
associated with a decreased binding of Mi-2β at the IL-2 promoter.  We also demonstrate 
that knockdown of Mi-2β inhibits IL-2 expression, supporting a model for FoxP3-mediated 
repression of transcription through the removal of factors required for optimal gene 
expression.  Thus, FoxP3 regulates gene expression at multiple levels, from transcription 
factor modulation to chromatin remodeling factor regulation.         
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Introduction 
 
Introduction Forward:  The primary goal of my graduate tenure and this 
introduction is to be as comprehensive and concise as possible, leaving no stone 
unturned unless technical difficulties inhibit my progress.  Therefore, I will not be giving 
a complete review of the HIV lifecycle for fear of boredom and for the fact that it has 
been extensively reviewed in the literature.  Therefore I will refer you to a fantastic 
review by Eric Freed (1) for a comprehensive look at HIV-1 replication.  Thank you and 
enjoy the following introduction to HIV, Foxp3 and Regulatory T cells. 
 
Part I: HIV infection overview 
 
Brief History and Emergence of HIV 
 The earliest documented case of HIV-1 infection came from a stored serum 
sample collected in 1959 from an adult Bantu male in the Democratic Republic of Congo 
(2).  Similarly, HIV-2 ancestors have dated back to the 1940.  Estimates by Korber et al. 
put the timing of HIV-1 M group divergence somewhere in the 1930’s (3).  Currently, it is 
proposed that HIV-1 came to humans from the chimpanzee, while HIV-2 has origins 
from the sooty mangabey, which harbor SIVcpz and SIVsm respectively (4-6).  In SIVsm’s 
natural host, which includes chimpanzees, sooty mangabeys and African green 
monkeys, SIVsm does not cause overt disease despite high viral load.  It is not until it is 
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present in an “unnatural” host (Rhesus macaque and humans for SIVsm and HIV, 
respectively) that disease progression is associated with chronic immune activation, T 
cell depletion and subsequent immunodeficiency.  This intriguing difference has formed 
the foundation for studies to determine the mechanisms of immunopathogenesis in HIV 
infection.        
 
Acute infection: A shift in the paradigm 
 HIV disease progression can be separated into 3 distinct phases: (i) acute 
infection occurring in the first 3-6 weeks in humans and 1-4 weeks in macaques, which is 
associated with a spike in viral load and a subsequent decrease in viral load to the viral 
set point; (ii) the chronic phase of infection lasting 6-10 years.  This asymptomatic phase 
coincides with a gradual increase in viral load and decrease in CD4+ T cell counts over 
time; (iii) and the final phase lasting roughly 12-18 months and is associated with AIDS 
and immune system failure (7).  The focus of past research has been to determine the 
mechanism of immune activation during the chronic phase and the resultant AIDS 
progression.  More recently, we have shifted our focus on what is happening during the 
acute phase of infection as a predictor of disease progression.  Now, HIV pathogenesis 
can be divided into two major phases; the acute infection phase associated with a 
dramatic loss of CD4+ T cells residing in mucosal tissue, and a chronic phase 
characterized by immune activation and gradual loss of peripheral CD4+ T cells over 
time (8). 
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  Looking more closely at the acute phase of infection, plasma viral load increase 
coincides with CD8+ T cell increases and a drop in CD4+ T cell counts (9).  This leads to 
an inversion of the CD4+/CD8+ ratio.  Until recently, the magnitude of CD4+ T cell 
depletion and its consequence were not fully appreciated.  Initial studies in 1998 using 
an SIV model described a profound depletion of CD4+ T cells in both the gut and gut-
associated lymphoid tissue (GALT) (10, 11), and more recent studies have described a 
similar depletion in the gut of HIV-1 infected individuals (12-14).  The importance of 
these findings is underscored by the fact that between 60-80% of the total CD4+ T cell 
population resides in the gut and associated lymphoid tissue (15).  The CD4+ T cell 
population that is most affected and depleted by SIV and HIV has a resting memory 
CD4+ phenotype, Ki-67- and CD69-, and CD45RA- (16).  Of greater importance is that the 
majority of mucosal CD4+ T cells are CD45RA-, and up to 75% express the HIV-1 
coreceptor required for T cell infection, CCR5 (12, 17, 18).  Thus, during the acute stage 
of infection, the resting memory T cell is a major target of SIV and HIV infection and 
depletion. 
 
The chronic phase of infection    
As previously stated, the chronic phase of HIV is associated with a steady decline 
in CD4+ T cell numbers, hyper-immune activation, and a slow and steady rise in viral 
load in patients not on ART.  In the gut, the depletion of CD4+ memory T cells continues 
and the restoration of this population is never achieved  in both pathogenic SIV and HIV 
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infection (11, 12).  As a consequence, chronic immune activation occurs due in part to 
homeostatic proliferation of the T cell pool to replenish the HIV-depleted pool, and also 
microbial translocation leading to LPS-mediated immune activation (19, 20).  
Interestingly, not only does HIV affect the dynamics of T cell homeostasis, but the 
function of CD4+ T cells is also impaired.  HIV-1 specific T cells are preferentially infected 
by HIV harbored in dendritic cells (21, 22) and have been shown to consequently lack 
effector function.  In general, disruption of immune homeostasis and subsequent overt 
immune activation are hallmarks of this phase of HIV-1 infection, and defining and 
characterizing the mechanisms contributing to immune activation is of great 
importance.  
 
Part II: The Role of Regulatory T cells in immune-balance- Do Tregs hold the key? 
In order to delineate the complicated mechanism behind HIV pathogenesis and 
progression to AIDS, you must first understand mechanisms of immune control.  
Therefore, the following section will be dedicated to describing and understanding a key 
player in immune homeostasis, the Regulatory T cell (Treg). 
 
Regulatory T cell in the Immune system: A brief history 
 The regulation of immune tolerance is a critical aspect of immunology.  The 
balance between recognition of self versus non-self is essential for maintenance of 
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immune homeostasis.  Excessive immune responses can have deleterious effects, as 
seen in autoimmune disease or immune pathology from infection or allergic insult.  
Similarly, understanding the mechanism of immune tolerance is beneficial in controlling 
tissue rejection following transplantation, or reversing unresponsiveness to autologous 
tumor cells.  The idea of an intrinsic T cell population capable of suppressing the 
immune system came to light in 1970 wherein the ability of T cells to both enhance and 
suppress immune responses was first described (23).  For several years following the 
initial discovery, both CD8+ and CD4+ suppressor T cell populations were described, but 
the inability to find a biological factor responsible for suppressor T cells led to a decline 
in suppressor T cell interest.  During the late 1980’s, T cell tolerance was discovered to 
be associated with mechanisms of clonal T cell deletion in the thymus (24, 25), and the 
discovery of secreted suppressive cytokines such as IL-10 further led to our thinking that 
a specific T cell subset was not required for tolerance (26). 
 Simultaneously, work on natural self-tolerance mechanisms was in place with 
the discovery in 1969 that removal of the thymus in neonatal mice resulted in ovarian 
destruction due to autoimmunity (27).  Importantly, removal of the thymus 3 days 
following birth resulted in several autoimmune manifestations (28), and work by several 
groups demonstrated that CD4+  T cells can be adoptively transferred into T cell-
deficient mice and cause disease (29).  Further work by Sakaguchi et al. in 1995 
demonstrated that a population of CD4+ CD25hi T cells was required for tolerance, 
wherein depletion of this population led to overt autoimmune disease while subsequent 
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addition of CD4+CD25+ T cells could control autoimmunity (30, 31).  Thus, there was a 
specific T cell population required to control the balance of the immune system.    
 
FOXP3 gene in Tregs  
In 2001, the discovery of the role of a transcription factor mediating 
autoimmune disease in mice can be considered the most important finding in Treg 
biology.  A member of the forkhead winged-helix family, Foxp3, when disrupted in the 
scurfy mouse resulted in a fatal lymphoproliferative disorder (32).  A disorder found in 
humans, IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome), was associated with mutation in the FOXP3 gene, and was characterized by 
autoimmune disease in multiple organs.  In 2003, multiple groups were able to show 
that Foxp3 protein localized to CD4+CD25+ T cells,  Foxp3 expression was required for 
Treg development and function, and expression of Foxp3 by retroviral transduction in 
CD4+CD25- T cells conferred a suppressive phenotype (33-35).  Through this work it 
became evident that Foxp3 is a critical factor in Treg function.  A more comprehensive 
look into the role of Foxp3 in Treg cells will be discussed in later sections. 
 
Mechanisms of Treg Suppression 
 Following the discovery of CD4+CD25hi Treg subset, several groups were able to 
isolation and further characterize the mechanism of Treg suppression activity.  Several 
groups showed that Tregs cultured in vitro with CD4+CD25- responder cells (or CD8+ T 
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cells for that matter) along with either APC-mediated stimulation or TCR stimulation 
with CD3 antibody was able to repress proliferation (36, 37).  Not only was it 
demonstrated that Tregs were able to suppress T cells in vitro, but Tregs also were 
characterized by an inability to produce IL-2, were hypoproliferative in vitro upon TCR 
stimulation, and furthermore, the mechanism of Treg suppression was cell contact-
dependent.  This lead to the current and ongoing research to discover the molecular 
mechanisms involved in Treg suppression. 
 As previously described, ectopic expression of Foxp3 in CD4+ CD25- is able to 
recapitulate the suppressive phenotype of Tregs almost completely.  In terms of Treg 
development in the thymus, Foxp3 expression is turned on 3 days following birth, 
correlating well with the previously described neonatal day 3 thymectomy-induced 
autoimmune disease (38).  Characteristic of Foxp3 expression was the increase in 
activation marker CD25, and other cell surface markers associated with T cell 
suppression such as CTLA-4 and GITR (33).  Several studies have shown the ability of 
Tregs to suppress several cell populations and cellular functions, including B cell 
proliferation and immunoglobulin production, the function of mature dendritic cells, NK 
and NKT cells, and importantly both naïve and memory CD4+ and CD8+ T cell 
populations (39-44).  Also of importance to note is the ability of Treg cells to suppress in 
an antigen specific and non-specific manner, the latter resulting in bystander 
suppression.   
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 To date, several mechanisms of suppression by Tregs have been demonstrated.  
With respect to cell-to-cell contact, upregulated cell surface factors such as CTLA-4 and 
LAG-3 have been shown to play a role in Treg suppression in vivo as demonstrated by 
administration of blocking antibodies for the specific factors in mice (45, 46).  Others 
have identified a role for cytokines in the suppressive activity of Tregs.  IL-10 secreted 
locally can control colitis and experimental allergic enchaphalomyelitis (EAE) (47, 48), 
while TGF-β is expressed on the surface of both human and murine Tregs and is 
required for suppression (40, 49).  An exact mechanism of suppression still remains to 
be resolved, although it is becoming clear that multiple mechanisms of suppression 
occur that are heavily dependent on the microenvironment, location of action and cell 
populations involved.       
 
The Role of Tregs in infection 
 The concept of the study of regulatory T cells was rejuvenated through work on 
autoreactive T cells and immune tolerance, but the impact of Tregs doesn’t stop there.  
It was clear that Treg cells would play a major role in infection, and Belkaid et al. 
provided the first evidence of the role of CD4+CD25+ T cells in the control of disease.  In 
this work, Leishmania major infection in mice when depleted of Treg cells was unable to 
establish a persistent infection and was cleared, due in part to a decrease in Treg cells 
and thus a consequent increase in CD8+ T cell-mediated parasite clearance.  This also 
firmly established a connection between sterilizing immunity and immune memory to 
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pathogens, and put Tregs in the forefront (50).  Within a year of this finding, Treg cells 
were also linked to control of the immune response to viral infection (44).  In the 
following sections, the role of Tregs in viral clearance and immunity will be discussed, 
and more significantly, their role in HIV infection. 
 Since Tregs were now implicated in immune tolerance and pathogen clearance, 
several groups set out to describe the role of Tregs in pathogen persistence.  
Experiments with Herpes Simplex virus (HSV) infection in mice showed that depletion of 
CD4+CD25+ T cells 3 days prior to infection resulted in elevated HSV-specific CD8+ T cell 
response in vivo in the acute and memory phases, and elevated HSV-specific CD4+ T cell 
responses (44, 51).  It became clear that the immune response to HSV infection was 
increased by Treg removal, wherein better memory response was decreased in the 
presence of Tregs, and protective immunity was compromised.  In the case of a second 
chronic disease, Hepatitis C virus (HCV), the study of Tregs is difficult due to a lack of an 
animal model.  Regardless, studies done in humans comparing chronic HCV-infected 
individuals to HCV-infected and recovered persons demonstrated a significant 
difference in the frequency of CD4+CD25+ T cells.  Persistently HCV-infected patients 
had an increased percentage of Tregs, and the Tregs were able to suppress HCV-specific 
CD8+ T cell responses ex vivo (52).       
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The Role of Tregs in HIV infection 
 Since the role of Tregs in establishing chronic versus acute diseases has been 
established for several pathogens, the importance of this cell population in HIV-1 
infection is of great importance.  Since the hallmark of progression to AIDS is the 
decrease in CD4+ T cells and hyper-immune activation, it is not unreasonable to 
rationalize the importance of Tregs in chronic immune activation.  The question remains 
if depletion of Tregs in HIV-1-infected patients contributes to uncontrolled immune 
activation.  Thus determining the kinetics and functional response of Tregs is of great 
importance.  Characterization of the role of Treg cells in HIV-1 infection has been 
controversial, most notably for the lack of consistent determination of a Treg phenotype 
and technical methods for determining Treg numbers in HIV patients, and lack of 
understanding of the dynamics of Tregs in peripheral blood over the time course of 
disease.  Thus, several groups have shown that Tregs numbers are either decreased (53-
57) or increased (58-61) in HIV-1 infection.  A clearer understanding of Tregs in disease 
progression has come to light due to the use of a monkey model of HIV infection.  As 
previously stated, SIV infection in African green monkeys and sooty mangabeys does not 
result in AIDS-like disease, while several groups have shown that rhesus macaque 
infection is an accelerated and consistent model for HIV disease progression (62-65).  
Thus, using this model, Periera et al. demonstrated that Treg numbers in peripheral 
blood of SIV-infected sooty mangabeys did not change over the course of infection, 
while there was a severe depletion in rhesus macaques.  Interestingly, the function of 
Tregs ex vivo was different between these two monkey models, and the apparent 
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numerical or function loss of Tregs correlated with viral load (66).  Similarly, Chase et al. 
described severe depletion of Treg cells in the gut of SIV-infected rhesus macaques 
during the acute and chronic phase of the infection, consistent with the finding that the 
majority of the CD4+CCR5+ T cell population is depleted in acute SIV infection (67).  
Surprisingly, none of these studies determined the relative level of infection of Tregs 
compared to memory T cells, although the Treg population was described in brief to 
harbor genomic SIV. 
 Given the importance for Tregs in immune-homeostasis, depletion would likely 
have a dramatic effect on T cell responses.  Depletion of T cells by direct infection or 
bystander apoptosis is well documented in HIV infection, and similarly Tregs in the 
lymphoid tissue have been shown to be infected by SIV, with approximately 13% of Treg 
cells being productively infected (58).  To date there have been no studies showing 
direct infection of Tregs in HIV infected individuals, although Tregs express the HIV 
receptor CD4 and coreceptor CCR5 and are highly susceptible to infection in vitro (53).  
In fact, our group has shown that HIV replicates more efficiently in Tregs than Teff cells 
(68), although others have demonstrated the opposite effect (69).  More recently, our 
group has shown that in humanized Rag2-/-γc-/- double knockout mice, HIV-1 is able to 
efficiently infect and deplete Treg cells (Jiang et al. manuscript submitted).  In this study, 
they also determined that depletion of Tregs through ONTAK treatment diminished the 
viral load and impaired T cell infection.  Clearly, the role of Treg infection and depletion 
requires further study to fully delineate their role in immune pathogenesis, viral 
pathogenesis and control of viral replication in all stages of disease.         
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PartIII: T cell activation  
 
T cells in the immune system  
 In vertebrates, the immune system is broken down into two separate divisions to 
ward off external insults and invading pathogens.  The innate immune response is an 
ancient component of the immune repertoire found in both plants and animals, and is 
vital in the recognition of infectious nonself from noninfectious self.  This arm of 
immunity is comprised of multiple cell types, including phagocytes such as dendritic 
cells, macrophages and neutrophils, along with eosinophils, mast cells, basophils and 
natural killer (NK) cells (70).  What distinguishes these cells from the adaptive immune 
arm is the recognition of nonself antigens with invariant receptors that do not require 
DNA rearrangement events.  Toll-like receptors are germline encoded and evolved to 
recognize patterns produced by metabolic processes of microbial pathogens but not 
host products.  Conversely, the adaptive immune response uses an entirely different 
receptor to mount an immune response to a specific pathogen.  These T cell receptors 
(TCR) are produced through somatic mutation and gene segment rearrangement to give 
a staggering array (~108) of TCR specificity (71).  This seemingly random recognition of 
antigens provides us with a response capable of specificity to foreign antigens and 
memory of infection, allowing for a faster and more efficient immune response.  
However, an innate drawback of this type of system is the inability to differentiate self 
from non-self, as seen in detrimental responses such as autoimmunity, allergy, and graft 
rejection. 
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 Specific pathogen recognition by CD4+ T cells occurs through the TCR and an 
interaction with a peptide/MHC class II complex.  A tightly regulated event, TCR 
activation results in a signaling cascade leading to proliferation, differentiation or even 
apoptosis (72).  The different subsets of CD4+ T cells include the interferon-gamma (IFN-
γ) producing Th1 cells, the IL-4 producing Th2 cells responsible for regulation of humoral 
immunity, and the newly emerging Th17 “pathogenic” T cells (73).  CD8+ T cells 
recognize endogenous antigens presented on MHC class I molecules found on all 
nucleated cells in the body, and are responsible for the clearance of infected cells.   
 
The T cell Receptor (TCR) signaling cascade  
 The TCR on resting T cells is comprised of an αβ heterodimer and is associated 
with the δ,γ,ε, and ζ chains to for the TCR/CD3 complex (74).  Following engagement of 
the TCR, a well defined signaling cascade is activated.  The cytoplasmic domains of the 
TCR contain immunoreceptor tyrosine-based activation motifs, or ITAMs, which are 
activated by phosphorylation of specific tyrosine residues by the src family kinase 
members Lck and Fyn (75).  The Syk family member ZAP70 is recruited to the TCR/CD3 
complex through interaction with the phosphorylated ITAM motifs, followed by 
interaction with and activation of the membrane adaptor molecule LAT (linker for 
activation of T cells) and SLP-76 (SH2-domian containing leukocyte protein of 76 kDa).  
Together, these later components nucleate a complex that includes the proteins Grb2, 
Vav-1, the p85 regulatory component of PI3K, Sos (son of sevenless), PLCγ1 
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(phospholipase Cγ1) , and GADS (Grb2-related adapter downstream of Shc) (reviewed in 
(76).  The major downstream target of this multisubunit complex is IP3 (inositol-1,4,5-
triphosphate) and DAG (diacylglycerol), which is hydrolyzed from PIP2 
(phoshatidylinositol 4,5 bisphosphate) mediated by the actions of PLCγ-1.  Immediately 
following IP3 production, calcium stored in the endoplasmic reticulum (ER) is released 
through the CRAC channels, and the increase in intracellular Ca2+ levels activates the 
Ca2+/calmodulin-dependent serine/threonine phosphatase calcineurin.  Activated 
calcineurin then dephosphorylates the transcription factor NFAT (nuclear factor of 
activated T cells) which localizes to the nucleus to regulate a variety of genes.   
The other component of that cascade, DAG, requires PLCγ-1 to directly target 
another serine/threonine kinase found associated with the TCR/CD3 complex, PKCθ 
(protein kinase C).  PKCθ when activated at the TCR interacts with a multisubunit 
complex called the CBM which contains CARMA1, Bcl10, and MALT1 (77).  This activated 
CBM complex is required for IKK activation, which subsequently phosphorylates IκBα 
leading to the release and nuclear import of NF-κB (78).  These two pathways of 
activating the transcription factors NFAT and NF-κB are the characteristic signaling 
products as a result of T cell activation, but are among multiple factors that lead to, and 
are required for, optimal T cell activation. 
 TCR stimulation alone is insufficient to activate a T cell to proliferate.  In fact, TCR 
stimulation without costimulation results in T cell unresponsiveness and anergy (79).  
Costimulation of TCR with CD28 is required for optimal T cell activation and IL-2 gene 
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expression, and studies in vivo have shown that blockade of CD28 leads to T cell anergy 
(80).  The ligands for CD28 are B7.1 and B7.2 (CD80 and CD86) and are expressed and 
upregulated on APCs following CD40-CD40L interaction between T cell and APC.  The 
signaling events following CD28 ligation by B7.1 and B7.2 requires similar adaptor and 
signaling molecules utilized by the TCR/CD3 pathway, thus the CD28-mediated signal is 
an enhancing signal and a threshold requirement of T cell activation (81).  In contrast, 
CTLA-4 is an inhibitory molecule found on activated T cells that has homology to CD28 
and a higher affinity for B7 receptors (82).  Thus, CTLA-4 acts to block CD28 receptor 
engagement and acts as an inhibitory receptor.  Other TCR costimulatory (B7h/ICOS)(83) 
and inhibitory (PDL-1/PD1)(84) receptor partners work together to regulate TCR 
activation and subsequent gene expression in T cells.  
      
Part IV: IL-2 promoter regulation- A model for T cell activation requirements 
  
Transcriptional regulation at the IL-2 promoter: the promoter defined 
 Initial work to determine the regulatory elements of the IL-2 promoter 
characterized an approximately 300 base pair sequence upstream of the TATA box in 
both murine and human T cells that was sufficient to drive the expression of a reporter 
gene in in vitro transfection experiments (85, 86).  Studies done in transgenic mice 
expressing only 500 bases of the proximal sequence of the IL-2 promoter, however, was 
unable to control positional effects of integration and tissue specificity of transcription.  
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Therefore more distal regions of IL-2 are required for full promoter regulation (87, 88).  
But for all intents and purposes, the 300 base pair region (proximal promoter) originally 
described encodes the transcription factor binding domains absolutely required for IL-2 
expression.  Since the early 1990’s, the transcription factors that bind to this minimal 
promoter have been intensely studied and described, and the following section will go 
into depth on the multiple factors and mechanisms of IL-2 gene expression with a focus 
on the proximal enhancer/promoter region. 
 
Transcriptional regulation at the IL-2 promoter: Transcription factors. 
 NF-κB- The transcription factor NF-κB plays a large role in several aspects of T 
cell function, including development, homeostasis, activation, survival and function.  
The importance of NF-κB is underscored by the effects of aberrant activities of NF-κB 
resulting in autoimmunity, cancer, and inflammation (89, 90).  NF-κB is a transcription 
factor representing a conserved group of proteins in the Rel family, which includes the 
members p65 (RelA), RelB, p50 (NF-κB1), p52 (NF-κB2) and c-Rel.  The Rel family can be 
separated into two distinct groups; (i) the RelA, RelB and c-Rel molecules are 
characterized by the conserved rel-homology domain and contain a transactivation 
domain; (ii) whereas the second group consists of the remaining p50 and p52 molecules 
which lack a transcriptional activation domain and are processed from large precursor 
proteins p105 and p100, respectively (91).  NF-κB is found dimerized in the cytoplasm 
retained by IκB's, a family which contains seven members which include IκBα, IκBβ, IκBε, 
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IκBγ, Bcl3, p100 and p105 precursors (92).  The predominant dimers of NF-κB found in T 
cells includes the p50 homodimer, the p50/c-Rel heterodimer, the p65/p50 
heterodimer, the latter two playing a substantial role in IL-2  transcriptional regulation 
(93).  As stated previously, activatin of TCR leads to a signaling cascade resulting in the 
activation of the IKK complex, proteosomal destruction of IκB followed by NF-κB 
translocation to the nucleus and activation of IL-2.  Although NF-κB is required for the 
optimal expression of IL-2, other factors play an equal if not more important role in 
transcriptional regulation. 
 NFAT/AP-1- The NFAT family of proteins plays a fundamental role in cytokine 
gene regulation in T cells.  This family contains five members which include NFAT1 
(NFATc2 or NFATp) which is found at high levels in resting T cells (94), NFAT2 (NFATc1 or 
NFATc) is induced following activation, NFAT3 (NFATc4), NFAT4 (NFATc3) and NFAT5.  
These members have a high sequence homology in the DNA-binding domains (DBD), 
which interestingly also have homology to the Rel/NF-κB DBD (95, 96).  In T cells and 
most notably at the IL-2 promoter, NFAT requires the concomitant binding of AP-1 for 
activity.  AP-1 binds the promoter in close proximity to at least three sites, with NFAT at 
two distinct sites, with Oct-1, and potentially two additional NFAT sites (97-100).  As 
previously outline, the activation of NFAT and AP-1 are both calcium-dependent, 
entering the nucleus following TCR stimulation.  There are other transcription factors 
necessary for complete IL-2 expression, such as Oct-1, NAB2, Bcl11B and others, but 
they are out of the scope of this introduction.  Remarkably, the inhibition of any one of 
the above transcription factors ablates IL-2 expression even though other factors are 
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still abundant.  This interesting notion brings us to the concept of the enhanceosome in 
IL-2 gene regulation. 
 
The IL-2 enhanceosome  
 One interesting model generated from the work of Rothenberg et al. is the 
concept of an enhanceosome-like mechanism to regulate IL-2 (93).  The concept of the 
enhanceosome was first modeled after the viral infection-inducible responsive gene IFN-
β (101, 102).  The concept follows the idea that an enhancer works as an integration 
platform, where specific factors triggered by specific responses must be available in an 
all or nothing assembly.  In the case of the INF-β enhanceosome, the high mobility group 
protein HMGI(Y) is required to bind the promoter/enhancer region, and any mutation in 
this site or other surrounding transcription factor binding sites nearly ablates all in vivo 
activity (103).  Similarly, at the IL-2 promoter, inhibition of one factor, such as NFAT, AP-
1 or NF-κB, single handedly inhibits gene activation.  A clear example of this occurs 
during anergy induction, wherein TCR activation without CD28 costimulation results in T 
cell unresponsiveness and no IL-2 induction.  Even more striking, Rothenberg goes on to 
demonstrate through in vivo footprint analysis that a lack of DNA-protein interaction is 
evident at the proximal promoter in unstimulated T cells, and only under optimal 
stimulation conditions does a DNA-protein footprint appear.  Addition of a calcium 
(NFAT) or NF-κB inhibitor, such as Cyclosporin A or forskolin, to an activated T cell 
results in dissolution of the footprint completely.  Thus, the enhanceosome-like complex 
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found at the IL-2 promoter is exceptionally unstable, requiring optimal signals and 
abundance of multiple transcription factors for activation.  Later sections will focus on 
the step preceding the binding of transcription factors to the IL-2 promoter, that is to 
say the role of chromatin remodeling required for gene expression.     
   
Transcriptional regulation of the HIV LTR: Lessons learned from IL-2? 
 HIV infects multiple cell types, from macrophages to lymphocytes, thymocytes, 
dendritic cells among others.  The ability of HIV to adapt to each of these cell types is 
apparent in studies comparing the capacity of HIV gene transcription in different cell 
types.  Unlike the above description of the enhanceosome-like complexity of the IL-2 
promoter, the HIV promoter only requires a few specific factors for optimal 
transcription.  Importantly, the transcription of HIV-1 LTR following integration into the 
genome occurs in two steps, (i) the early phase requires host transcription factors for 
initiation of transcription, and (ii) the late phase transcription which requires the HIV-1-
encoded viral protein Tat (104).  The basic architecture of the HIV LTR is divided into 3 
regions, the U3 (nucleotides -453 to -1), R (+1 to +98) and U5 (+99 to +180), which 
contains the regulatory element (-453 to -104), enhancer (-105 to -79) and core domains 
(-78 to -1) (all found in the U3) along with the TAR regulatory domain (+1 to +60) found 
in the R region (105).  The basal transcription elements of HIV LTR required in all cell 
types resides in the core promoter region, and includes the TATA box for binding of host 
transcriptional machinery and the adjacent Sp1 transcription factor binding sites (106, 
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107).  Sp1 is able to recruit or synergize with activation factors such as COUP-TF (108), 
NF-κB (109), and Tat (110), and has been reported to recruit CyclinT1 for Tat-
independent transcription (111).  The importance of this region is underscored by the 
fact that deletion of the core promoter ablates LTR transcription in all cells types. 
 The enhancer region described previously contains two adjacent NF-κB binding 
sites with an overlapping NFAT binding site.  The NF-κB sites are critical for optimal LTR 
activity.  Similar to the IL-2 promoter, the most abundant NF-κB factor found in 
activated T cells, the p65/p50 heterodimer, is largely responsible for binding to and 
activating the LTR.  Deletion of the NF-κB binding sites greatly reduces the ability of viral 
replication in CD4+ T cells and other cell types as well.  An interesting and not fully 
understood interplay also occurs in this region.  The NFAT binding site overlaps the NF-
κB binding site, and therefore based on stearic hindrance, binding of these two factors 
are mutually exclusive at this site.  The importance of NFAT in LTR transcription is 
supported by the observation that NF-κB and Sp-1 mutant viruses replicate in CD4+ T 
cells upon phorbol ester and Ionomycin stimulation.  NFAT has been shown to be both a 
positive and a negative regulator of LTR transcription.  Specifically, NFAT1 has been 
shown to be a transcriptional activator and repressor in CD4+ T cells (112-114), while 
NFAT2 has been shown to only activate the LTR (115).  It is not all together clear the role 
that the different NFAT and NF-κB factors play in binding to the LTR, but differential 
abundance of each factor in unstimulated CD4+ T cells and stimulated cells is intriguing.  
As noted earlier, there is an abundance of NFAT1 in unstimulated cells, and NFAT2 levels 
rise sharply in an activation-dependent manner.  One could imagine a situation where 
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NFAT1 would be inhibitory to LTR expression in naïve T cells, whereas NFAT2 might be a 
more potent activator of LTR and is abundant in stimulated T cells.  Thus it is intriguing 
to speculate that HIV-1 LTR has adapted to use most efficiently the transcription factors 
that are available under conditions favorable for replication.  This theory is supported by 
Mouzaki et al. when they described a repression-derepression mechanism in primary T 
cells that is NFAT dependent (116).  Although NFAT and NF-κB are the two key enhancer 
molecules that have been heavily studied and described, a region just upstream of the 
enhancer contains a regulatory element capable of binding multiple factors in a cell and 
environment specific way, and a comprehensive review can be found elsewhere and 
thus is not a focus of this review (104).   
 One keys aspect of HIV replication is the innate ability of the virus to adapt to 
multiple cellular environments, both as an efficient way of replication and evasion of 
immune responses.  Not so surprisingly, the LTR has also evolved to exploit the 
mechanisms of the host cell, and thus has an exquisite ability to respond to host cell 
stimuli.  With respect to the HIV LTR, the IL-2 promoter acts as a model of activation-
dependent regulation of gene transcription.  The following chapters will focus on 
another important method of promoter regulation, focusing on chromatin structure and 
factors responsible for regulation of chromatin remodeling at both the IL-2 and LTR 
promoters.   
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Part V: Chromatin remodeling         
 
Chromatin remodeling at the IL-2 promoter  
 Insights into the regulation of the IL-2 promoter were provided by studies 
determining the tissue specificity of IL-2 expression.  So far, tissue-specific transcription 
factors have yet to be revealed, leading investigators to search for the possible 
mechanism of promoter regulation by chromatin modification.  Early studies by 
Rothenberg’s group demonstrated the dynamics of cis-regulatory regions in the first 600 
base pairs upstream of the transcription start site.  In the 5’ region flanking the proximal 
promoter, approximately -510 to -313, is maintained in an open chromatin 
conformation in both unstimulated and stimulated CD4+ T cells (117).  This is in stark 
contrast to the proximal promoter, -300 to -45, which is restructured within 1-2 hours 
following antigenic stimulation (118).  More importantly, the distal promoter region 
maintains DNA/protein interactions, suggesting a role of this region in nucleosome 
remodeling.  In 2001, Attema et al. described a positioned nucleosome located from -
200 to -60, which following activation, is remodeled and associated with loss of histones 
H3 and H4 and a decrease in histone acetylation (119, 120).  Thus, the current model of 
histone dynamics and chromatin remodeling at the IL-2 gene is a regulatory complex 
positioned just upstream of the proximal promoter that contains bound factors in 
unstimulated T cells.  Upon stimulation, these factors facilitate the destabilization of the 
nucleosome positioned at the proximal promoter, followed by binding of transcription 
factors required for optimal IL-2 transcription.  It is currently unknown which factors 
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contribute to or are required for chromatin accessibility at the IL-2 promoter, but the 
role of ATP-dependent chromatin remodeling factors is likely required. 
 
ATP-dependent chromatin remodeling complexes 
 In eukaryotic cells, histone modifying enzymes and also ATP-dependent 
chromatin modifying complexes play a crucial role in unraveling or relaxing tightly 
bound chromatin to allow access to transcription factors (121, 122).  Enzymes such as 
histone acetyltransferases (HAT) and histone deacetylases (HDAC) modify specific 
residues on histone tails, and other molecules are known to regulate the 
phosphorylation, methylation and ubiquitination as ways of tightly regulating histone 
dynamics (122-124).  While covalent modifications actively repress or activate 
transcription of various promoters, other mechanisms of chromatin remodeling are in 
place, including DNA methylation, the use of histone variants, and histone displacement.  
The latter will be the focus of this section, wherein we discuss the mechanism of histone 
displacement and the requirement of ATP-dependent chromatin remodeling complexes.  
 The nucleosome consists of 146 base pairs of DNA wrapped twice around a 
histone octamer containing two copies of H2A-H2B and H3-H4 dimer pairs, which can be 
further packaged with linker histones (H1) to create higher order structures.  The exact 
mechanism of nucleosome remodeling remains elusive, and “remodeling” refers to the 
process of altering the DNA-histone interaction in a process requirimg ATP hydrolysis.  
Several models of nucleosome remodeling exist, including sliding, twisting and looping, 
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and these are reviewed in Cosgrove et al. (125). The result is chromatin that has been 
freed from nucleosomal interaction, allowing for other factors to bind.  Four members 
of ATP-dependent chromatin remodelers responsible for maintaining this chromatin 
fluidity includes SWI/SNF (switching defecting/sucrose non-fermenting), ISWI (imitation 
SWI), the INO80 (inositol requiring 80) and the Mi-2/NuRD (nucleosome remodeling and 
deacetylation) complexes.  We will focus on the latter in the following section. 
 
The Mi-2/NuRD complex: Dynamic regulator of transcription. 
 The ATPase containing molecule of the Mi-2/NuRD complex is Mi-2β (CHD4).  
The CHD family, a subclass of the SWI/SNF family, contains CHD1-5 and are 
characterized by conserved ATPase domain, PHD finger domain, chromodomains and a 
putative DNA-binding domain (126).  The two most widely studied CHD members, CHD3 
and CDH4 (Mi-2α/β) were initially identified as autoantigens found in dermatomyositis, 
a disease of the connective tissue (127, 128).  As its name states, the NuRD complex is 
high molecular weight complex that bridges two fundamental actions of chromatin 
remodeling, ATPase activity and histone deacetylation.  Associated with the Mi-2/NuRD 
complex are HDAC1 and HDAC2 which are responsible for the main deacetylase 
function, the H4 interacting proteins RbAp46/48, methyl-CpG binding molecules 
MBD2/3, and the metastasis associated (MTA) family members MTA1-3 (129-132).   
 Mi-2β is the main subunit containing the ATPase activity.  By itself it can interact 
with chromatin but not free DNA or histone, and the ATPase function is required in 
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nucleosome displacement (133, 134).  As stated previously, the reported HDAC function 
of the Mi-2/NuRD complex has been shown to be critical for the repression of a 
multitude of promoters.  Even though Mi-2β contains a putative DNA binding domain, it 
can be targeted to promoters through the interaction with transcription factors such as 
Bcl6, ikaros and Bcl11B (135-137).  Interestingly, the first loss-of-function study 
described a role for Mi-2β in the activation of the CD4 gene in developing thymocytes.  
This was the first study to show that Mi-2β was able to act as an activating complex 
through its association and recruitment of p300 HAT (138).  Other groups have shown 
that Mi-2β can act as an activator or repressor of transcription depending on the 
association of Mi-2β with RET Finger Protein (RFP) and Brg1 biochemically (139).  Thus, 
ATP-dependent chromatin remodeling factors are required for differential regulation of 
gene transcription by multiple mechanisms. 
 So far, the molecules responsible for increasing the chromatin accessibility at the 
proximal IL-2 promoter following activation have not been described.  The role Mi-2β at 
the IL-2 promoter has not been previously determined, although several factors that are 
known to associate with the Mi-2/NuRD complex, such as NAB2 and Bcl11B, are factors 
required for the activation of the IL-2 promoter in vivo (137, 140-142).  More 
importantly, these ATP-dependent chromatin remodeling factors are important in the 
regulation of IL-2 in regulatory T cells.  The fact that murine Treg cells fail to undergo 
proper chromatin remodeling across the proximal IL-2 promoter supports the role of 
chromatin remodeling factors in gene regulation (143).      
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Chromatin remodeling at the LTR 
 Transcription of the HIV LTR follows integration into the target chromosome, 
with a preference for regions of active replication (144, 145).  The chromatin structure 
of the LTR has been extensively studied for the prospect of understanding how viral 
latency is regulated.  Two nucleosomes are positioned on the LTR, nuc-0 is bound to the 
Regulatory Element in the U3 region encompassing -415 to -255, while nuc-1 is found in 
the Tar Element located in the +10 to +155 region of the R domain (146-148).  Upon T 
cell stimulation, nuc-1 is known to actively remodel, and histone acetylation is known to 
regulate LTR transcription (149, 150).  The HAT p300 is recruited by p65 interaction to 
acetylate histones and activate the LTR (151).  Under conditions of viral latency, such as 
resting or unstimulated cells, the LTR is occupied by a p50 homodimer associated with 
HDAC1 (152).  Similarly, YY1 and LSF have also been shown to recruit HDACs to maintain 
a hypoacetylation state of histones (153).  It is clear that there are multiple levels of 
regulation of both the IL-2 and LTR promoters including both transcription factors and 
chromatin remodeling.  The next section will be devoted to the role of HDACs in 
promoter regulation. 
 
Part VI: Role of Histone deacetylases (HDACs) in T cell and HIV gene expression 
 
General overview of HDACs and HDAC inhibitors 
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 HDACs are the enzymes that mediate the removal of acetyl groups from the ε-
amino groups of lysine residues.  Originally named for their role in the removal of acetyl 
groups from histones, it is well known that other proteins are also deacetylated by 
HDACs.  The HDAC family has 18 total members separated into groups based on 
phylogenetic analysis and homology with yeast HDACs (154).  Class I HDACs includes 
HDAC1-3 and 8, class II is comprised of group IIa which includes HDAC4,5,7 and 9, and 
IIb containing HDAC6 and 10.  Class III contains SIRT1-7, and class IV contains HDAC11.  
In general, class I HDACs remain nuclear while the class II HDACs are able to shuttle 
between the nucleus and cytoplasm.  HDACs have become extremely promising 
therapeutic targets due to their aberrant expression and association with cancer 
(reviewed in (155)), and HDAC inhibitors (HDACi) have shown therapeutic potential in 
several hematologic malignancies (156-158). 
 The most extensively studied HDACs are the class I and II proteins.  All HDACs in 
these two classes contain similar catalytic domains, the HDAC domain.  Unlike the class I 
HDACs, class II HDAC contain an extended amino-terminal adapter domain that has 
been shown to interact with several transcription factors (reviewed in (159)).  The 
contribution of the catalytic domain of the class II HDACs in transcriptional repression 
has been disputed.  Attempts to successfully isolate recombinant forms of class II HDACs 
with enzymatic activity has been elusive (160, 161), and natural splice variants of HDAC9 
lacking the HDAC catalytic domain or overexpression of the N-terminus alone is able to 
associate with full HDAC activity (162, 163).  More recently, Lahm et al. demonstrated 
evidence that class II HDACs contain a conserved histidine in the catalytic domain that is 
29 
 
different from class I HDACs, which instead contain a tyrosine at this site.  Swapping the 
histidine 976 for a tyrosine conferred class I enzymatic levels to class II enzymes, and 
vice versa.  Thus, class II HDACs intrinsically contain low deacetylase activity and require 
associated class I molecules in vivo (164).       
 
Biological role of HDACi 
 HDACi in treatment of cancer has been shown to selectively kill tumor cells, 
which are approximately tenfold more sensitive to HDACi induced apoptosis (165).  
Though the mechanism is not completely understood, evidence of apoptosis induction 
through death receptor extrinsic pathways, mitochondrial pathways, reactive oxygen 
species (ROS) production, and cell cycle arrest have all been described (reviewed in 
(166)).  There is increasing evidence for a role of HDACi in immunomodulation, the 
enhancement of anti-tumor immune targeting.  Groups have shown that HDACi 
upregulates MHC class I and II molecules, costimulatory molecules such as CD40, CD80, 
CD86 and ICAM1 to augment the immunogenicity of tumor cells (167, 168).  The HDACi  
suberoylanalide hydroxamic acid (SAHA) can suppress acute graft-versus-host disease 
(GVHD) through modulation of cytokine production (169).  Recently, the Hancock group 
determined that in vivo administration of the HDACi TSA along with rapamycin was able 
to enhance Treg-mediated suppression of inflammatory bowel disease, induce islet 
allograft survival and donor-specific allograft tolerance.  In this study, TSA enhanced the 
expression of Foxp3, and increased Treg numbers and enhanced Treg suppressive 
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activity on a per cell basis (170).  Taken together, HDACs play a large role in immune 
regulation and cellular activity.    
 
HDACs and HDACi on the IL-2 promoter 
 As stated in the previous sections, HDACs play an extensive role in gene 
regulation in immune cells.  Approximately 2-8% of gene are enhanced or repressed by 
HDACi (171-174), and in a recent study of HDAC1-specific knockdown in embryonic stem 
cells, approximately 7% of the genes were dysregulated (175).  Surprisingly, a number of 
genes were enhanced or inhibited by HDAC1 knockdown or HDACi, due to both direct 
effects and indirect effects.  In T cells, IL-2 transcription has been shown to be 
downregulated upon HDACi treatment, although the specific HDAC targeted by HDACi 
administration was not investigated (176-178).  One of the downstream targets of 
HDACi is NF-κB.  Specifically, it has been shown that HDACi can alter the transactivation 
activity of NF-κB without altering nuclear localization or DNA binding activity.  Still, 
others have shown that HDACi can enhance NF-κB nuclear localization, and there is 
evidence that HDACi can differentially regulate NF-κB in a cell-dependent manner.  
Recently, Matsuoka et al. demonstrated HDACi disrupts the HDAC4/N-CoR complex as a 
mechanism of IL-2 repression (179), thus class II HDACs can regulate IL-2.  It remains to 
be examined if class I HDACs can regulate IL-2 transcription.       
 
HDACs and HDACi on HIV LTR 
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 LTR regulation by HDACi has been described by multiple groups using TSA, 
trapoxin (TPX), valproic acid (VPA) and sodium butyrate (NaBut).  The addition of these 
inhibitors leads to an increase in nuc-1 acetylation and thus transcriptional activation of 
LTR that are transiently transfected, stably integrated and in the context of 
reconstituted chromatin templates (150, 180-186).  The viral protein Tat is 
hyperacetylated upon HDACi treatment leading to more efficient transcriptional activity.  
Similar to IL-2, regulation of p65 by deacetylation affects the activity of HIV LTR.  
Removal of the NF-κB elements inhibited the effects of HDACi on the LTR (183).  
Interestingly, addition of TSA or NaBut resulted in the prolonged nuclear localization of 
p65/p50, and also delayed the reappearance of cytoplasmic IκB through an IKK-
dependent activation.  Therefore, HDACi is able to affect the activity of NF-κB not only 
through regulation of acetylation, but also through upstream mediators of the NF-κB 
pathway.       
 
Regulation of HDACs   
      HDACs play important roles in multiple processes of transcriptional regulation 
and are therefore tightly regulated.  Several HDACs are found in large multiprotein 
complexes and are thus regulated by association with cofactors.  As previously stated, 
purified recombinant class II HDACs are enzymatically inactive, thus association with in 
vivo binding partners will regulate HDAC activity.  HDAC1 and HDAC2 are found in at 
least three different multisubunit complexes, including the Mi-2/NuRD (see previous 
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section), Sin3 and CoREST complexes (129, 132, 187-189).  Separate from complex 
formation, HDACs can also be covalently modified in vivo.  Several groups have 
demonstrated phosphorylation of HDAC1 and HDAC2 at multiple sites, and it appears as 
though the extent of phosphorylation results in differential HDAC enzymatic activity 
(190-192).  Others have shown that HDAC1 can be modified by sumoylation at lysine’s 
444 and 476, although the functional activity following modification remains to be 
clarified (193, 194).  Interestingly, there have been multiple reports of viral proteins 
regulating HDACs through association in vivo.  The Adenoviral gene product Gam1 
inhibits HDAC1 deacetylase activity through changes in sumoylation (194), and CMV 
immediate early 1 (IE1) and IE2 proteins are able to inhibit HDAC3 through unknown 
mechanisms (195). 
 
Part VII: Foxp3 Regulation of gene transcription 
 
Foxp3 gene expression signature- a ‘master regulator’? 
 The notion of Foxp3 as a “master regulator” or “lineage commitment” factor has 
been scrutinized and the role of Foxp3 in gene regulation has been extensively studied.  
The hallmark of a lineage factor is that the presence or absence of the factor is sufficient 
to confer or preclude a particular phenotype.  Such a role for Foxp3 was identified on 
the basis that loss of function results in severe immunodeficiency, and that retroviral 
transduction of Foxp3 restored suppressive ability to a degree (33, 34).  Evidence that 
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Foxp3 might not be absolutely required for Treg function exists.  Nearly all human T cells 
contain some level of Foxp3 following activation without any obvious suppressive 
activity (196, 197).  In human IPEX patients, a select population of T cells with regulatory 
activity was able to persist in the absence of Foxp3 gene expression (198).  Consistent 
with this notion, several groups have also shown T cells with characteristics of Treg cells 
in the periphery of mice in the absence of Foxp3  (199, 200).  Hill et al. extensively 
looked at the gene signature of Treg cells, both natural and induced under several 
conditions, and concluded that Foxp3 is perhaps one of several factors required for the 
full phenotype of a Treg cell (201).  Studies utilizing transgenic mice with GFP coding 
sequence inserted into the Foxp3 locus, GFP+ Foxp3-less mice, showed that several 
features of Treg cells are maintained in GFP+ Foxp3-less cells (199).  The current 
hypothesis is that Foxp3 stabilizes or amplifies features of chronic TCR stimulation, 
although several features of Treg function, such as suppression and cell cycle 
progression, are highly dependent on Foxp3 (201, 202).  In this regard, genes such as 
Ctla4, GzmB and others required for negative regulation of T cell signaling are further 
amplified by Foxp3 expression or reduced in GFP+ Foxp3-less cells.  Foxp3 is also able to 
override other developmental T cell pathways, such as Th17, Th1 and Th2 programs, 
demonstrated by the increased expression of related cytokines in the absence of Foxp3 
(199, 203-205).  Importantly, the level of Foxp3 expression is crucial to Treg function.  
FILIG mice, which harbor a mutation resulting in low expression levels of Foxp3, show a 
accelerated onset of autoimmune disease (204).  Similarly, transient expression of Foxp3 
in humans occurs in most all T cells, and only the high expressing Tregs are suppressive.  
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Regardless, Foxp3 is required for a set of critical functions of Treg cells, and the 
mechanisms of Foxp3-mediated gene regulation will be reviewed in the following 
sections. 
 
Foxp3 protein structural analysis 
 In order to understand the function of Foxp3 in transcriptional regulation, the 
organization, domains and binding partners must be identified and characterized.  The 
Foxp3 protein is approximately a 47kDa protein containing 431 amino acids in humans 
and 429 in mice with approximately 86% homology.  Foxp3 protein is characterized by 4 
functional domains; the N-terminus contains a proline-rich region contained in amino 
acids 1-193, a C2H2 zinc-finger motif (200-223), a leucine-zipper-like motif (240-261) 
and a carboxy-terminal forkhead domain (338-421).  Insight into the functional role of 
these domains is demonstrated in IPEX patients, where natural mutations of FOXP3 
have been described for every domain except the zinc-finger.   To date, 13 mutations 
have been described in IPEX patients.  A mutation in the proline-rich region, del 249 (T) 
in exon 2, results in a frameshift and early termination (206).  Two mutations are found 
in the leucine zipper region, both of which are codon deletions (del770-772 and del772-
774) in exon 7 (207, 208).  The Forkhead domain contains 5 separate missense 
mutations, R347H, I363V, F371C, A384T and R397W (206, 208-210).  Other mutations 
include mutations in the stop codon, resulting in C-terminal extensions, a splice site 
mutation in the 5’ end of exon 5, and an A to G transition at position +4 in intron 8 
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causing the deletion of exon 9 (207, 209-211).  Studies with various IPEX mutants have 
demonstrated multiple roles of these domains in Foxp3 function.  The leucine zipper has 
been show to be required for oligomerization in vivo, wherein deletion of amino acids 
250 or 251 results in a loss of Foxp3 homotetramerization or Foxp1/Foxp3 
heteromerization (212-214).  Interestingly, mutations in the leucine zipper domain  
disrupt binding and transcriptional function, but does not impair association of Foxp3 
with a multiprotein complex.  Analysis by the Ziegler group demonstrated that the N-
terminus and forkhead domain are required for repression of targeted promoters, with 
the proline-rich region alone capable of repression, and the forkhead domain required 
for DNA binding and nuclear localization.  Also, while disruption of the leucine zipper 
was necessary and sufficient to abrogate multimerization, a mutation disrupting the zinc 
finger of Foxp3 (C204S) had no effect on Foxp3 multimerization and had only a mild 
effect on repression of a targeted promoter (214).      
 
Regulation of Foxp3 protein 
 Currently two isoforms of Foxp3 are found in human Treg cells, a full length 
transcript and an exon 2 deleted form (215, 216).  Murine Foxp3 protein is only 
expressed in the full length form and found to be completely nuclear (217).  Conversely, 
the full length human Foxp3 (Foxp3a) is found both in the cytoplasm and nucleus while 
the truncated isoform (Foxp3b) is nuclear only due to a lack of a putative nuclear export 
signal (NES) contained in this region (218).  Induction of Foxp3 gene expression in Treg 
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cells is currently being studied.  Several groups have documented the ability of TGF-β to 
convert T cells into Treg cells (219, 220), and recent investigation of the Foxp3 promoter 
has demonstrated a dependence of NFAT, Sp1, AP-1, STAT5 and, more recently, Smad3 
for Foxp3 activation (221-223).  While the factors regulating Foxp3 expression are under 
intense investigation, a more thorough look into the temporal regulation of Foxp3 gene 
expression and the transcription factors required will give insight into the requirements 
for Treg development, function and maintenance.   
 
Mechanisms of Foxp3 regulation of promoter activity  
 Extensive studies on the gene profile of Treg cells along with ChIP-Chip 
(microarray on immunoprecipitated chromatin) experiments determining the direct 
targets of Foxp3 protein has produced insight into the requirement of Foxp3 protein for 
the Treg signature.  It is now evident that multiple signals, including TGF-β signaling, IL-2 
receptor signaling and Foxp3 converge to impart this Treg signature.  Nevertheless, 
there are multiple characteristic promoters that are directly regulated by Foxp3, 
including IL-2, Ctla4, Tnfrsf18 (GITR) among others.  The mechanisms of Foxp3 
regulation of these promoters will be discussed in the following paragraph. 
 Foxp3 was initially described by Bettelli et al. to functionally interact with and 
inhibit the transactivation activity of the transcription factors NFAT and NF-κB (224).  
More biochemical and structural analysis of the interaction of Foxp3 and NFAT was 
described by Wu et al., wherein mutations in the forkhead domain abrogating NFAT and 
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Foxp3 interaction was able to inhibit Foxp3 promoter occupancy and regulation of 
several characteristic genes.  Thus, a model was proposed where Foxp3 was able to 
inhibit an activating NFAT:AP-1 complex by promoting a repressive NFAT:Foxp3 complex 
at the IL-2 promoter (225).  More recently, Foxp3 was also demonstrated to inhibit AP-1 
DNA binding activity to further inhibit AP-1-dependent genes such as IL-2 (226).  Reports 
from Grant et al. and our published data point to a role of Foxp3 in transcriptional 
regulation of retroviral promoters.  In both cases, the HIV-1 promoter was regulated by 
Foxp3-mediated modulation of NF-κB, although with disparate results (68, 69).  
Interestingly, two studies showed an increase or ‘stabilization’ of transcription factors at 
various promoters regulated by Foxp3, correlating with the notion that Foxp3 might play 
a role of enhancing or stabilizing a TCR-mediated signal (68, 225).  Factors involved in T 
cell development also interact with Foxp3 to regulate targeted promoters.  The 
Sakaguchi group described an interaction with Foxp3 and AML1/Runx1 transcription 
factor.  In this study, AML1/Runx1 bound to a region upstream of the core enhancer 
region of the IL-2 promoter and enhanced IL-2 expression.  A Foxp3/AML1 complex was 
able to bind this region and was shown to be required for Foxp3 repression of IL-2 (227).     
 Foxp3 regulates the expression of various promoters at multiple levels.  Several 
groups have demonstrated an increase or decrease in histone acetylation of promoters 
regulated by Foxp3 (68, 225, 228).  In accordance with this notion, factors modulating 
histone acetylation, such as HATs and HDACs, have been shown to interact with and be 
recruited by Foxp3 to various promoters.  Li et al. describes an ensemble of Tip60 (HAT), 
HDAC7 and Foxp3 in the regulation of IL-2.  They demonstrated that the presence of 
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these three factors together optimally suppressed gene expression, and knockdown of 
any one of these factors inhibited Foxp3 repression of IL-2 (229).  More recently, work 
from our lab and others has shown an interaction of Foxp3 with linker histone H1b 
(Mackey-Cushman manuscript in preparation) and histone H1/H5(230), respectively, 
which are required for Foxp3 regulation and suppressive function.  Thus, it is becoming 
abundantly clear that Foxp3 regulates multiple T cell pathways and we are just now 
beginning to unravel the complex nature of Foxp3 gene regulation in Treg cells.          
  
 
Scope of this dissertation 
 This dissertation is encompasses the emerging role of Foxp3 in multiple aspects 
of the immune system.  The purpose of the following chapters is to characterize several 
mechanisms of Foxp3 function.  The first chapter will demonstrate a disparate role for 
Foxp3 protein in the regulation of the IL-2 promoter and the HIV LTR in human Treg 
cells.  Through a yet unknown mechanism, Foxp3 activates the HIV-1 LTR by stabilizing 
the transcription factor NF-κB bound to the HIV promoter.  The second chapter focuses 
on a novel function of Foxp3 in Treg cells.  Here, we demonstrate that Foxp3 inhibits the 
activity of HDAC1 in human T cells.  We also show that this function is important for 
promoter regulation, since knockdown of HDAC1 inhibits Foxp3-mediated repression or 
activation of various promoters.  Finally, the third chapter demonstrates a role for Foxp3 
in the regulation of IL-2 gene expression through chromatin remodeling factors.  We 
39 
 
show that the ATPase Mi-2β is required for IL-2 activation, and expression of Foxp3 is 
associated with a decrease in Mi-2β binding at the proximal promoter.  Herein, we 
describe multiple novel mechanisms for Foxp3-mediated gene regulation through 
transcription factor regulation and chromatin remodeling factor modulation.  The 
implications of these findings and future directions will be discussed in the final chapter. 
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Abstract 
 
FoxP3 determines the development of CD4+CD25+ regulatory T (Treg) cells and 
represses IL-2 expression in Treg cells.  However, HIV-1 infects and replicates efficiently 
in FoxP3+ Treg cells.  We report that, while inhibiting IL-2 gene expression, FoxP3 
enhances gene expression from HIV-1 LTR.  This Foxp3 activity requires both the N-
terminal and C-terminal domains, and is inactivated by human IPEX mutations.  FoxP3 
enhances HIV-1 LTR via its specific NF-κB binding sequences in an NF-κB-dependent 
fashion in T cells but not in HEK293 cells.  FoxP3 decreases level of histone acetylation at 
the IL-2 locus but not at the HIV-1 LTR.  Although NF-κB nuclear translocation is not 
altered, FoxP3 enhances NF-κB-p65 binding to HIV-1 LTR.  These data suggest that FoxP3 
modulates gene expression in a promoter sequence-dependent fashion by modulating 
chromatin structure and NF-κB activity.  HIV-1 LTR has evolved to both highjack the T 
cell activation pathway for expression and to resist FoxP3-mediated suppression of T cell 
activation. 
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Introduction 
 
Although clearly generated in the thymus (1), CD4+CD25+ Treg cells can also be 
generated from mature T cells in the peripheral organs (2, 3).  Recent genetic studies in 
both mouse and human have identified FoxP3, a Forkhead transcription factor, as a 
master determinant of Treg development and function (4-7).  Mutations in the FoxP3 
gene in Scurfy mice or human IPEX patients lead to lymphoproliferative and 
autoimmune phenotypes due to impaired Treg cells.  Importantly, ectopic expression of 
FoxP3 in naïve CD4+CD25- T cells leads to inhibition of IL-2 expression and Treg-like 
suppression activity (8).  FoxP3+ Treg cells have been implicated in a number of 
pathologic processes including elevated levels in cancers (9-11) and infectious diseases 
(12-15), and reduced levels in autoimmune diseases (16-20).  With chronic HCV infection 
in human and chimps (21-23), and friend leukemia virus in mice (14), Treg cells are 
induced to subdue the anti-viral immune responses and allow persistent infection.   
 HIV-1 disease or AIDS progression, however, is associated with overt immune 
activation.  Since the beginning of the AIDS epidemic, it has been documented that 
chronic immune activation is a reliable predictor of AIDS progression (24-26).  
Interestingly, SIV infection in its native hosts is non-pathogenic, characterized by high 
SIV replication, limited immune responses, and long-lasting Treg induction (27-29).  In 
HIV-1 infected patients, conflicting findings have been reported regarding Treg cells.  
FoxP3+ Treg cells are generally depleted in parallel to the total CD4+ T cell population 
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during disease progression (30).  In some reports, increased levels of Treg cells are 
documented in lymphoid tissues (31, 32), whereas others have observed decreased 
levels of Treg cells and FoxP3 expression in peripheral blood (13, 33-35).  However, in 
rhesus monkeys acutely infected with SIV, FoxP3+ Treg cells are induced and are 
productively infected by SIV (36).  Thus, it is not clear how HIV-1 infects and replicates in 
Treg cells in vivo. 
 One clear function of FoxP3 is to suppress expression of IL-2 in Treg cells.  Direct 
FoxP3 binding with NFAT has been reported to prevent its association with AP-1 and 
contribute to suppression of IL-2 gene expression (37).  Moreover, FoxP3 has been 
demonstrated to occupy the IL-2 promoter to inhibit gene expression by altering histone 
acetylation levels, thus changing the chromatin structure (38).  In addition, FoxP3 has 
been reported to inhibit NF-κB activity in transfected 293 cells or T cells (39, 40); 
however, others have failed to show such inhibitory effect in human T cells (37).  Both 
NFAT and NF-κB are also involved in regulating HIV-1 gene expression (41).  Although 
NF-κ B activates HIV-1 LTR, the effect of NFAT on LTR is controversial.  NFATc1 is 
reported to upregulate HIV-1 gene expression by binding to the overlapping NF-κ B sites 
(41), and NFATc2 has also been shown to upregulate HIV-1 replication in primary CD4+ T 
cells (42).  In other reports, however, NFATc2 is shown to competitively bind to the LTR 
NF-κ B sites and inhibit LTR activity (43, 44).   
 Given that FoxP3 inhibits T cell activation and expression of cytokines such as IL-
2 via inhibiting NFAT and NF-κ B, one surprising recent finding reports that Treg cells 
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support higher levels of infection by HIV-1 or FIV compared to FoxP3-CD4+ T cells in 
vitro (13, 45).  Two lines of evidence have also indicated that HIV-1 infection and 
replication in Treg cells may be important in vivo.  First, recent reports have 
documented that, although less than 5% of total CD4+ T cells from peripheral blood are 
CD25+FoxP3+ Treg cells, up to 50% of CD4+ T cells express FoxP3 in mucosal lymphoid 
organs from HIV-1 (46) or SIV (36) infected human or monkeys, respectively.  Therefore, 
the FoxP3+ Treg cells can provide a significant number of target cells for HIV-1 infection 
in lymphoid organs.  Remarkably, 13% of the FoxP3+ T cells are shown to be 
productively infected by SIV in the lymphoid organs of acutely infected animals (36).  
Therefore, FoxP3+ Treg cells are important target cells for HIV-1 infection and 
replication, at least in mucosal lymphoid tissues during acute infection.  Treg induction 
in HIV-1 infected lymphoid organs may contribute to suppressed anti-HIV immunity and 
establishment of persistent HIV infection.  It is therefore critical to investigate how HIV-
1 infects and replicates in these T cells for both virological and immuno-pathogenic 
reasons. 
 Here we report that FoxP3 enhances HIV-1 LTR but inhibits IL-2 promoter 
activity.  This FoxP3 activity requires both the N- and C-terminal domains and maps to 
the N-terminus (including the Proline Rich Region, PRR) and the C-terminal Forkhead 
domain and is inactivated by human IPEX mutations.  We also demonstrate that FoxP3 
enhances HIV-1 LTR via specific NF-κB binding sequences in an NF-κB-dependent 
fashion.  FoxP3 also enhances a minimal promoter with the NF-κB sequences derived 
from LTR but not from the MHC promoter in Jurkat cells, but represses both the HIV-1 
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LTR and MHC promoter in 293T cells.  Interestingly, FoxP3 reduces the acetylation level 
of the IL-2 promoter but increases acetylation of HIV-1 LTR.  Furthermore, FoxP3 
enhances NF-κB occupancy at HIV-1 promoter in T cells but does not alter NF-κB nuclear 
translocation or levels.  The data suggest that FoxP3 modulates gene expression in a 
promoter sequence-dependent fashion by modulating chromatin structure and NF-κB 
activity.  HIV-1 LTR has evolved to both highjack the T cell activation pathway for 
expression and to resist FoxP3-mediated suppression of T cell activation. 
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Experimental Procedures 
 
Plasmids, antibodies and cell lines.  FoxP3 was cloned into the HSPG retrovirus 
vector (47).  LTR linker scanning mutants (48), LTR-luc, LTR deletion or point mutants, 
minimal promoter with LTR 3x-κB-luc (41) were previously reported.  Mis-sense 
mutations identified from IPEX patients (8) (I363V, F371C, A384T and R397W) were 
introduced in the FoxP3 cDNA by site-directed mutagenesis.  Deletion mutants in FoxP3 
were generated by PCR amplification to specifically remove the N-terminus (aa 1-189) as 
in FoxP3-ZFLZFKH, the N-terminus including the Zinc-finger (aa 1-241) as in FoxP3- 
LZFKH, or the N-terminus including all domains except Forkhead (aa 333-429) as in 
FoxP3-FKH.  MHC-3x-κB-luc and IκB-SR plasmids were provided by A. Baldwin (UNC-
Chapel Hill, NC, USA).  Jurkat cells were maintained in RPMI 1640 (Gibco BRL), 293T cells 
were maintained in DMEM and primary human T cells were maintained in Iscoves MEM, 
supplemented with 10% FBS (Sigma), 2mM L-glutamine, 100 U/ml penicillin, and 100 P 
mg/ml Streptomycin.  For T cell activation, mouse anti-CD3 and CD28 (BD Biosciences) 
and Goat anti-mouse IgG (Caltag) antibodies were used.  To determine T cell purity, anti-
human CD25-PE (Miltenyi) and CD4-FITC (BD Biosciences) were used.  7AAD (Molecular 
Probes) was used to determine cell viability.   
 
 Retrovirus production and transduction.  293T cells were co-transfected with 
retroviral vector, VSV-G and gag/pol containing plasmids as previously described (47).  
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For production of single cycle HIV-Luc reporter virus, 293T cells were transfected with 
VSV-G and HIV-Luc plasmids by Effectene (Qiagen, Valencia, CA).  For retroviral 
transduction, Jurkat cells were spin-noculated with HSPG control or FoxP3 retrovirus to 
>95% efficiency as measured by GFP expression (47).   
 
 Cell culture and T cell purification and transfection. CD4+ primary T cells were 
purified from Ficoll separated PBMC by MACS human CD4+ T cell isolation kit (>95% 
purity, Miltenyi-Biotech, Auburn, CA).  CD4+ T cells were activated by anti-CD3/CD28 
mAb crosslinked by plate-bound anti-mouse IgG as previously described (49).  Briefly, 
purified cells are stained with anti-CD3 (0.5ug/ml) and anti-CD28 (1ug/ml) and 
incubated on plated-bound goat anti-mouse IgG.  Purified primary CD4+ T cells were 
transfected by Amaxa nucleofector kit (Amaxa Biosystems, Gaithersburg, MD).  Briefly, 
5x10P6 P  unstimulated CD4+ T cells were transfected with 5μg plasmid DNA (>40% 
efficiency by GFP expression), and cultured for 48 hours before infection with the VSV-G 
pseudotyped HIV-luciferase reporter virus and activation by CD3 and CD28 crosslinked 
with plate-bound IgG.  Cells were activated for 48 hours and luciferase was measure by 
luciferase assay.  Alternatively, T cells were transduced with vector or FoxP3 retrovirus 
(>60% efficiency by GFP) and infected with VSV-G pseudotyped HIV-luciferase virus.   
 
 IL-2 measurement by real-time qPCR and ELISA.  Amaxa-transfected primary CD4+ 
T cells were sorted for GFP expression and activated with anti-CD3/CD28 as above.  IL-2 
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mRNA levels were determined following activation.  5x10 P3 P cells were lysed in Trizol 
Reagent (Invitrogen) and column purified (RNeasy, Qiagen).  cDNA was generated using 
Cells-to-cDNA II kit (Ambion, Austin, TX) and quantitative PCR performed on ABI Prism 
7000 (Applied Biosystems) using TaqMan IL-2 probe/primer set (Applied Biosystems).  
Each sample was normalized to 18s.  To measure IL-2 production in Jurkat T cells, 
transduced Jurkat cells were stimulated with PHA and Ionomycin (1uM) for 12 hours 
(41) and supernatants were collected.  Secreted IL-2 was quantitated by the Human IL-2 
ELISA kit (BD Biosciences, San Diego).   
 
 Transfection of Jurkat T cells and luciferase assay.  Jurkat cells were transfected 
using Geneporter transfection reagent (Genlantis, San Diego, CA) and transfection 
efficiency was monitored by GFP expression or cotransfection with pAX-βgal reporter 
plasmid.  Cells were lysed and luciferase expression was determined by Luciferase Assay 
System (Promega).  Experiments were done in triplicates and repeated at least three 
times. 
 
 ChIP assays.  Jurkat T cells with a stably integrated HIV-1 LTR were transduced 
with control or FoxP3-expressing vectors.  Sonicated chromatin from the Jurkat cells was 
IP'ed with control IgG (IgG) or p65 (a kind gift from Al Baldwin) or anti-AcH3 by 
chromatin immunoprecipitation assay kit per manufactures instruction (Upstate, 
Millipore).  Samples were purified and subject to real-time qPCR analysis.  The relative 
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p65 binding or acetylation of IL-2 or LTR promoter is expressed with ratios of ChIP-
specific signal divided by signals from control 10% input chromatins.  IL-2 promoter was 
analyzed with Taqman reagents using the following primers: 5’-cac cta agt gtg tgg gct 
aat gta ac-3’ and 5’-ctg atg act ctt tgg aat ttc ttt aaa cc-3’ and a FAM:TAM probe 5’-aga 
ggg att tca cct aca tcc att cag tca gtc-3’.  This amplicon spans -226 to -133 in the human 
IL-2 promoter and spans the NF-κB and AP-1 sites.  HIV-1 LTR was analyzed with 
SyberGreen reagents (Abgene, UK) using the primers (5’-agc cct cag atc ctg cat ata agc a-
3’ and 5’- gtt agc ca gaga gct ccc agg ctc a-3’) that yield an amplicon spanning -44 to +49. 
 
 EMSA.  Standard EMSA were performed (50).  Briefly, probes containing the NFB 
site (GGGATTCCCC) from the MHC gene or HIV-1 LTR were labeled with P32 PP-dCTPP Pusing 
Klenow.  10μg of nuclear extract was incubated with probe.   For antibody supershift or 
blocking, 2μg of α-p65, α-p50 or control IgG were added to nuclear extract and labeled 
probe.   
 
 Western Blot. 1x10P6 P Jurkat T cells were lysed in 0.5% NP-40 lysis buffer and 
resolved by 10% SDS-PAGE.  Approximately 25μg of proteins were used and FoxP3 was 
probed with an anti-FoxP3 antiserum (51), α-rabbit–IgG–HRP and visualized by 
ECL(AmershamP PBiosciences).   
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 Statistical analysis.  For statistical analysis, a two-tailed Student t-test is employed 
where P<0.05 is considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 66 
 
Results 
 
FoxP3 differentially modulates IL-2 and HIV-1 gene expression by inhibiting IL-2 
but enhancing LTR promoter activity.  To investigate the mechanism of HIV-1 
replication in FoxP3+ T cells, we expressed FoxP3 in the human CD4+ T leukemia (Jurkat) 
cells.  When Jurkat cells were infected with VSV-G pseudotyped HIV-1 containing 
luciferase reporter gene, elevated levels of HIV-1 gene expression were detected in both 
unstimulated and stimulated FoxP3+ T cells (5-8 fold, Fig. 2.1A).  Retrovirus-mediated 
expression of FoxP3 in Jurkat cells inhibited the expression of IL-2 upon activation (>6 
fold, Fig. 2.1B).  To determine if FoxP3 similarly regulates expression of IL-2 and HIV-1 in 
primary CD4+ T cells, we expressed FoxP3 in purified primary CD4+ T cells.  HIV-1 gene 
expression was significantly enhanced in Th cells previously transduced with FoxP3-
expressing retroviral vector (Fig. 2.1C) or by Amaxa nucleofection (data not shown).  In 
contrast, ectopic expression of FoxP3 in CD4+ T cells efficiently suppressed expression 
from the endogenous IL-2 gene (Fig. 2.1D).  Thus, FoxP3 inhibits IL-2 expression but 
enhances HIV-1 gene expression in human T cells.   
 To determine if FoxP3 regulates expression of IL-2 and HIV-1 at the promoter 
level, we transfected IL-2 or HIV LTR promoter constructs driving the luciferase gene 
into Jurkat T cells.  Similar to NL4-luciferase virus infection, FoxP3 also enhanced gene 
expression from HIV-LTR (Fig. 2.2A).  FoxP3 efficiently suppressed IL-2 gene expression 
from both the endogenous IL-2 gene (Fig. 2.1B&D) and from the transfected IL-2 
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promoter (Fig. 2.2B).  The HIV-1 LTR co-transfection experiment was performed in the 
absence of Tat.  Therefore, HIV-1 Tat is not required for the FoxP3 activity. 
 
The Forkhead domain and N-terminus of FoxP3 are critical for FoxP3-mediated  
enhancement of HIV-1 LTR.  The Forkhead domain and distinct residues in FoxP3 are 
critical for FoxP3 function as indicated by mutations in the scurfy mouse and in human 
IPEX patients (8).  To define the FoxP3 domains that contribute to this LTR enhancing 
activity, we generated FoxP3 deletion mutants and transduced Jurkat T cells.  Loss of the 
N-terminus, including the Proline Rich Region, inhibited FoxP3 enhancement (Fig. 2.3A) 
while expression of the N-terminus alone was not able to enhance LTR activity (data not 
shown).  We also tested the known mis-sense mutations derived from IPEX patients by 
single site-directed mutagenesis introduction into full length FoxP3.  Interestingly, all 4 
such mis-sense mutations tested also inactivated the FoxP3 activity in enhancing HIV-1 
LTR (Fig. 2.3B).  Similar levels of the mutant FoxP3 proteins were expressed (Fig. S2.1).  
Therefore, the FoxP3 activity in enhancing HIV-1 LTR depends on both the N-terminal 
domain and critical residues in the forkhead domain which are also critical for the 
function of the FoxP3 protein in humans. 
 
The two NF-B sites in the LTR enhancer core are both required for FoxP3 
enhancement.  We have mapped the cis-acting elements in HIV-1 LTR that respond to 
FoxP3 by employing the 26 linker scanning mutants (LS1-LS26) of HIV-1 LTR (48).  The 
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mutations in LS20 (-111 to -94) and LS21 (-93 to -76), which inactivate the two NF-κB 
binding sites in the LTR enhancer core, significantly reduced response to FoxP3 (Fig. 
2.4A).  Deletion of the NF-κB/NFAT enhancer core completely abolished LTR response to 
FoxP3 (Fig. 2.4B).  The two NF-κB sites also overlap with the sites for NFAT binding (41).  
Point mutations in either NF-κB site (LTR mB1 and mB2) significantly reduced FoxP3-
mediated enhancement while mutations in both sites (mn-κB) led to complete loss of 
enhancement by FoxP3 (Fig. 2.4B).  Therefore the two NF-κB sites in the LTR enhancer 
core are both required for FoxP3 enhancement.   
 
FoxP3 enhances HIV-1 LTR activity in NF-B sequence- and cell type-specific 
fashions.  To further elucidate the role of NF-κB, we blocked NF-κB activation using the 
IκB super-repressor in T cells.  Consistent with results that the NF-κB sites in LTR were 
critical for FoxP3-mediated activation, FoxP3 was unable to enhance HIV-1 LTR activity 
when NF-κB function was inhibited (Fig. 2.5A).  We also determined if FoxP3 
enhancement was specific to the LTR-derived NF-κB sequences.  A luciferase reporter 
gene driven by a minimal promoter with 3 NFB sites derived from HIV-1 LTR (LTR-3κB-
luc) or from the MHC gene (MHC-3κB-luc) was studied in Jurkat cells.  Under the same 
experimental conditions, FoxP3 enhanced LTR-3κB-luc expression but not the MHC-3κB-
luc expression in T cells (Fig. 2.5B).  Interestingly, both LTR-3κB-luc and MHC-3κB-luc, as 
well as the LTR-luc were inhibited by FoxP3 in 293T cells (Fig. 2.5C&D), corroborating 
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results previously described for FoxP3 in 293T cells (39, 40).  Thus, FoxP3 modulates HIV-
1 LTR activity via its specific NF-κB sites in T cells. 
 
FoxP3 differentially alters the acetylation level of the IL-2 promoter and HIV 
LTR.  We tested if FoxP3 affects the chromatin structure at the IL-2 promoter and the 
HIV-1 LTR by ChIP assays with anti-acetylated histone H3-K9 (AcH3) antibodies.  Relative 
levels of AcH3 were determined by qPCR of the NF-κB and NFAT/AP-1 region (-226 to -
133) in the human IL-2 promoter after ChIP (Fig. 2.6A).  FoxP3 reduced the AcH3 level or 
the “openness” of the IL-2 promoter in Jurkat cells either unstimulated or after 
stimulation.  When the stably integrated HIV-1 LTR in the same Jurkat A82 (52) cell was 
analyzed, we discovered that FoxP3 either had no effect (unstimulated) or increased 
(stimulated) AcH3 acetylation level at the NF-κB /Sp1 enhancer core sequences of the 
LTR (1.8-fold, p<0.05, Fig. 2.6B).  Thus, FoxP3 reduced the histone acetylation level of 
the IL- 2 promoter but had no effect or increased that of the HIV-1 LTR in T cells.  
 
FoxP3 does not alter NFB nuclear translocation, but modulates NFB 
occupancy at the HIV-1 LTR promoter.  Given that FoxP3 enhancement is both NF-κB 
sequence- and cell type-specific, it is unlikely that a simple increase in the nuclear levels 
of NFB is involved.  Indeed, FoxP3 did not enhance NF-κB nuclear localization in Jurkat 
cells by Western blot analysis (Fig. 2.7A).  Using a consensus NF-κB probe, similar levels 
of p65/p50 and p50/p50 NF-κB DNA binding activity were detected in FoxP3+ and vector 
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control cells (Fig. 2.7B).  We next wanted to determine if FoxP3 was able to modulate 
NF-κB occupancy at the HIV-1 LTR promoter in vivo by chromatin immunoprecipitation 
(ChIP) using specific anti-p65 antibodies.  In a Jurkat T cell line stably integrated with the 
HIV-1 LTR (53), FoxP3 enhanced the association of p65 at the LTR promoter (~2 fold, Fig. 
2.7C) but not at the IL-2 promoter (Fig. 2.7D).  Therefore, although NF-κB nuclear 
translocation was unchanged, FoxP3 enhanced p65 occupancy specifically at the HIV-1 
LTR in T cells.   
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Discussion 
 
 FoxP3 inhibits T cell activation and IL-2 expression in T cells, but high levels of 
HIV-1 or FIV infection are reported in FoxP3+ Treg cells in vitro (13, 45, 54).  Since HIV-1 
LTR activity is closely coupled to T cell activation and IL-2 gene expression, we studied 
how FoxP3 modulates IL-2 gene expression and HIV-1 replication in T cells.  We report 
that, while inhibiting IL-2 promoter, FoxP3 enhances HIV-1 LTR.  This FoxP3 activity is 
inactivated by human IPEX mutations.  FoxP3 enhances HIV-1 LTR via its specific NF-κB 
binding sequences in an NF-κB-dependent fashion in T cells but not in HEK293 cells.  
FoxP3 decreases level of histone acetylation at the IL-2 locus but not at the HIV-1 LTR.  
Although NF-κB nuclear translocation is not altered, FoxP3 enhances NF-κB binding to 
HIV-1 LTR.  These data suggest that FoxP3 modulates gene expression in a promoter 
sequence-dependent fashion by modulating chromatin structure and NF-κB activity.  
HIV-1 LTR has evolved to both highjack the T cell activation pathway for expression and 
to resist FoxP3-mediated suppression of T cell activation. 
 HIV-1 infection of Treg cells is well-supported by a number of studies in vitro and 
in animal models in vivo.  In fact, HIV-1 (or FIV) can replicate more efficiently in human 
(or feline) Treg cells in vitro compared to Th cells (13, 45, 54).  It is likely that HIV-1 LTR 
has evolved to resist FoxP3-mediated mechanisms that inhibit IL-2 expression in FoxP3+ 
Treg cells.  Several recent reports have indicated that 1) Treg cells can serve as a 
significant target population for HIV-1 infection in vivo and 2) these FoxP3+ Treg cells 
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support productive HIV-1 infection in vivo.  Although about 5% of total CD4+ T cells from 
normal peripheral blood are CD25+FoxP3+ Treg cells, up to 50% of CD4+ T cells express 
FoxP3 in mucosal lymphoid organs from HIV-1 (46) or SIV (36) infected human or 
monkeys.  In addition, it has been reported that virtually all human CD4+ T cells 
upregulate FoxP3 upon activation and have transient suppressive activity (55).  Thus, 
FoxP3+ T cells can provide a significant number of target cells for HIV-1 infection.  
Remarkably, 13% of the FoxP3+ T cells are shown to be productively infected by SIV in 
the lymphoid organs of acutely infected animals (36) whereas 30-60% of memory CD4 T 
cells in these organs have been reported to harbor SIV proviral genomes (56-58).  In 
comparison, <1% total infection are detected by qPCR of HIV-1 proviral genomes in 
blood CD4+ memory T cells from HIV-1-infected patients (59, 60).  Therefore, FoxP3+ 
Treg cells are important target cells for HIV-1 infection and replication, at least in 
mucosal lymphoid tissues during acute infection.     
 The distinct modulation of LTR and IL-2 expression by FoxP3 may be due to 
specific LTR NF-κB binding sequence, or to the unique FoxP3-mediated NF-κB activity 
and chromatin remodeling.  Based on a recent report (61), the HIV-1 LTR-derived NF-κB 
site would have a 2-3 fold lower affinity relative to the MHC- or IL2-derived NF-κB sites 
(D. Holmes and L. Su, unpublished).  FoxP3 may differentially affect the IL-2 and HIV-1 
promoter by altering the cooperative binding of p65-p50 with other transcription 
factors in T cells.  While our data suggests that NF-κB is critical for FoxP3 enhancement 
of HIV-1 LTR, the role of NFAT should be clarified because NF-κB and NFAT share 
overlapping binding sequences at the LTR enhancer core.  IL-2 expression is critically 
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dependant on NFAT and AP-1 activity.  Wu et al (37) describes a model in which FoxP3 
binds NFAT to displace AP-1, thus inhibiting IL-2 expression.  The direct inhibition of 
NFAT transcriptional activity by FoxP3 (8, 39) may also lead to preferential inhibition of 
IL-2.  Interestingly, FoxP3 binding at the promoters of CD25 and CTLA-4 is also 
accompanied by increased NFAT binding, suggesting that FoxP3 stabilizes NFAT on those 
promoters (37).  While NFATc1 and NFATc2 have both been reported to enhance HIV-1 
gene expression in some reports (41, 42), NFATc2 (or NFAT1) can also inhibit HIV-1 LTR 
by competitively binding to the NF-κB core sequences (43, 44).  It is thus likely that 
FoxP3 may inhibit NFATc2 binding at competing LTR NF-κB sites and lead to increased 
NF-κB binding and LTR expression.  However, our data do not support the involvement 
of NFAT.  First, FoxP3 enhanced HIV-1 LTR expression in unstimulated Jurkat cells (Fig. 
1A, 2A) where no NFAT activity is detected.  Second, mutations in the LTR NF-κB binding 
sites blocked FoxP3-dependent enhancement, but mutations that specifically inhibit 
NFAT binding to the LTR (41) did not affect the enhancement (Fig. 2.4, and D. Holmes 
and L. Su, unpublished results).  Finally, inhibition of NFAT activation by FK506 did not 
affect FoxP3-mediated enhancement of LTR (D. Holmes and L. Su, unpublished results), 
while enhancement of LTR by FoxP3 depended on NF-κB activation (Fig. 2.5A).  Thus a 
new FoxP3 activity may be involved in modulating the NF-κB activity and in enhancing 
HIV-1 gene expression. 
 Similar to stabilized NFAT and FoxP3 binding at the promoters of IL-2, CD25 and 
CTLA-4 (37), the increase in NF-κB binding at the LTR in Jurkat cells may be due to a 
similar FoxP3-mediated stabilization.  This is supported by the fact that IPEX mutations 
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in the forkhead DNA binding domain ablated FoxP3’s activity on LTR (Fig. 2.3).  However, 
it is not clear if FoxP3 directly binds to specific LTR sequences.  The physical interaction 
of FoxP3 with NF-κB is also controversial.  Although FoxP3 is shown to interact with NF-
κBwhen overexpressed in 293T cells (39)others (37) and our study (D. Holmes and L. 
Su, unpublished results) have failed to detect such interaction.  Similar to its interaction 
with NFAT (37), FoxP3 may also interact with NF-κB in a DNA sequence-dependent 
fashion.   
 A recent report has documented that FoxP3 represses HIV-1 LTR by inhibiting 
NF-κB in T cells as well as in 293 cells (40).  In contrast, we observed that FoxP3 inhibited 
HIV-1 LTR in 293T cells but enhanced its activity in T cells (Fig. 2.5).  The apparent 
discrepancy in T cells may be due to different experimental models and procedures.  We 
analyzed HIV-1 gene expression mostly from T cells infected with reporter HIV-1 
pseudotyped with VSV-G, whereas the previous report is based only on transient 
transfection of promoter-reporter assays.  The FoxP3 effect on HIV-1 LTR also depends 
on the activation condition of T cells.  We observed enhancement of LTR by FoxP3 in T 
cells either unstimulated or stimulated with anti-CD3/CD28.  However, low or no 
significant enhancement by FoxP3 was observed following stimulation with PMA and 
ionomycin in T cells (D. Holmes and L. Su, unpublished results).  The activation 
conditions used in the previous study are not clear (40).  Therefore, transfection or 
infection methods, and relative levels of activation may contribute to the discrepancy.  
In addition, the C-terminal Forkhead domain of FoxP3 is required for the reported FoxP3 
activity in 293T cells but not in T cells (40).  Most human IPEX mutations reside in the 
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Forkhead domain, suggesting that the reported FoxP3 activity in inhibiting NF-κB and 
HIV-1 LTR in T cells may not be a critical FoxP3 activity.  Our data concludes that both 
the N-terminus and Forkhead domains are essential for FoxP3 to enhance HIV-1 LTR, 
consistent with the findings by Wu et al. (37) that both domains of FoxP3 are required 
for repression of IL-2 and activation of CD25 and CTLA-4. 
 FoxP3 has recently been demonstrated to inhibit IL-2 and INF- gene expression 
by reducing the histone acetylation and thus altering their chromatin structure.  
Conversely, promoters activated by FoxP3  (such as CD25, GITR and CTLA-4) have 
increased levels of acetylation in FoxP3-expressing cells (38).  Our findings support a 
model wherein expression of FoxP3 leads to increased NF-κB occupancy at the HIV-1 LTR 
and elevated histone acetylation in T cells.  The altered chromatin structure at the LTR 
may promote NF-κB occupancy in FoxP3-expressing T cells.  Since the FoxP3-mediated 
effect is correlated with increased AcH3 level at the LTR, CD25 and CTLA4 loci but 
decreased AcH3 level at the IL2 gene locus (Fig. 2.7A and (38)), FoxP3 may modulate 
activity of specific HDAC or HAT in a promoter-dependent fashion in T cells.  
Alternatively, recruitment of HDAC or HAT by NF-κB protein to HIV-1 LTR (62, 63) may 
be altered by FoxP3 and contribute to the differential gene modulation. 
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Figure 2.1.  FoxP3 inhibits IL-2, but enhances HIV-1 gene expression in T cells. 
(A) Vector or FoxP3 transduced Jurkat T cells were infected with VSV-G pseudotyped NL4-Luc virus 
and non-activated or CD3/CD28 stimulated.  At 48 hours post-infection, cells were lysed and assayed 
for luciferase expression.  (B) Vector control and FoxP3 transduced Jurkat cell were non-activated or 
activated with PMA and Ionomycin for 24 hours and supernatants assayed for IL-2 by ELISA.  (C)  
Primary CD4+ T cells transduced with FoxP3 or control vector and infected with VSV-G/NL-4-
Luciferase virus and relative HIV-1 gene expression was measured at 48 hpi.  (D) Primary CD4+ T 
cells transfected with control vector or FoxP3 plasmid (sorted based on GFP) were activated with 
anti-CD3/CD28 and cultured for 2 days.  Cells were harvested for relative IL-2 expression by real-
time RT-PCR.  Data represents 3 independent experiments done in triplicates.  (*, p<0.05)   
 
 
 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  FoxP3 inhibits IL-2 promoter, but enhances HIV-1 LTR expression in T cells.   
Jurkat T cells were transiently transfected with HIV-1 LTR (A) or IL-2 promoter (B) driven luciferase 
constructs in the presence of control vector or FoxP3 plasmid.  For IL2-luciferase assay, Jurkat cell 
were non-activated or activated with PMA and Ionomycin at 36 hours post transfection.  Luciferase 
gene expression relative to vector control cells was measured at 48 hpi.  Data represents >5 
independent experiments done in triplicates.  (*, p<0.05)   
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Figure 2.3.  A critical activity of FoxP3 is required for LTR enhancement.   
(A) Deletion mutants of FoxP3 were made as described in methods.  Jurkat cells transduced with 
retrovirus containing no insert control (PG), wild type FoxP3 (FP3), FoxP3 C-terminus (FP3C, aa191-
420), FoxP3 lacking the N-terminus and Zinc Finger (FP3LZFKH, aa241-420), or the Forkhead domain 
of FoxP3 (FP3-FKH, aa333-420) were infected with the VSV-G NL4-Luciferase virus and luciferase 
activity was measured 48 hours post infection.  Proline-rich region (PRR), zinc finger (ZF), leucine 
zipper (LZ), and Forkhead domain (FKH) are labeled. (B) FoxP3 genes with indicated IPEX mis-sense 
mutations are cotransfected into Jurkat cells with HIV-1 LTR-luciferase.  (*, p<0.05)   
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Figure 2.4  FoxP3-mediated LTR enhancement maps to the NFB sites.   
(A) Linker scanning (LS1-LS26) mutants (48) replacing every 18 bp of HIV-1 LTR were cotransfected 
into Jurkat cells with vector or FoxP3 as above and lysates were assayed for LTR-driven luciferase 
expression.  Data are representative of 3 independent experiments each done in triplicates.  
LS20/LS21 mutants affect the two NFB sites in the LTR.  (B) HIV-1 LTR containing mutations ablating 
specific binding by NF-κB (41) were cotransfected with control vector or FoxP3 in Jurkat cells, and 
results are summarized from 3 independent experiments.   
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Figure 2.5  FoxP3 affects LTR expression via an NF-κB sequence-dependent and cell type 
dependent mechanism. 
(A) LTR enhancement by FoxP3 is ablated by IκB-super repressor (IκB-SR(50)).  LTR-luciferase is 
transfected with IκB-SR and vector or FoxP3 plasmid into Jurkat cells.  (B/C) LTR enhancement by 
FoxP3 is specific for the LTR NF-B sites.  Luciferase reporters driven by multiple copies of LTR or 
MHCII (50) NF-B sites were transfected into Jurkat cells (B) or 293T cells (C) with vector control or 
FoxP3.  (D) FoxP3 represses in 293T cells.  293T cells transfected with vector control or FoxP3 with 
HIV-1 LTR luciferase reporter plasmids.  Experiments were done in triplicates and lysates are assayed 
for luciferase expression. 
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Figure 2.6. FoxP3 differentially affects the Histone 3 acetylation level of the IL-2 and HIV-1 LTR 
promoters.   
Jurkat A82 T cells with a copy of stably integrated HIV-1 LTR were transduced with vector or FoxP3 
(>95% GFP+).  Sonicated chromatins from activated Jurkat cells were IP'ed with control IgG or anti-
acetyl-H3 Ab (AcH3).  (A) FoxP3 reduces the acetylation of histone H3 at the IL-2 promoter.  ChIP 
analysis of vector or FoxP3 transduced Jurkat A82 T cells was performed.  Samples were purified and 
subject to qPCR analysis with the IL2 promoter amplicon spanning the NFB and NFAT/AP-1 sites (-
226 to -133) in the human IL-2 promoter.  (B) FoxP3 increases H3 acetylation at integrated HIV-1 LTR 
locus.   The same Jurkat A82 T cells with a stably integrated HIV-1 LTR were analyzed by anti-AcH3 
ChIP for HIV-1 LTR core enhancer sequences by qPCR.  Error bars indicate SD of triplicate samples.  
*, p<0.05 
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Figure 2.7. FoxP3 alters NF-κB occupancy to the LTR promoter. 
 (A) FoxP3 expression does not affect NF-κB localization in the nucleus.  Vector control and FoxP3 
transduced Jurkat T cells were fractionated, cytoplasmic and nuclear lysates were separated by SDS-
PAGE.  Membrane was probed for NF-κB using anti-p65 antibody.  (B) FoxP3 does not alter NFB 
p65 and p50 binding to the MHCII-derived consensus NF-κB probe.  Nuclear extract of transduced 
Jurkat T cells were left unstimulated or PMA/Ionomycin stimulated for 30 minutes and NF-κB 
binding was assessed.  Antibodies specific for p65 and p50 were used for supershift.  (C-D) Jurkat T 
cells with a stably integrated HIV-1 LTR were transduced with control or FoxP3-expressing vectors.  
Sonicated chromatins were IP'ed with control IgG or anti-p65 Ab.  Samples were purified and subject 
to real-time qPCR analysis.  Input chromatin (10% relative to each IP) was used to normalize 
samples.  The relative p65 occupancy at the HIV-1 LTR (C) or IL-2 promoter (D) from a representative 
experiment is shown as relative anti-p65-specific ChIP signals divided by signals from control input 
chromatins.  (**, p<0.01)   
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Figure S2.1   
(A) Schematic diagram of FoxP3 protein domains and its deletion mutants, and their expression by 
Western blot of myc-tagged FoxP3 deletion mutants expressed in 293T cells.  (B) Western blot of 
FoxP3 IPEX mutants in 293T cells and a schematic representation of mis-sense IPEX mutations 
relative to known forkhead domain structures. 
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Abstract 
 
FoxP3 plays a crucial role in the development and function of CD4+CD25+ Regulatory 
T cells.  FoxP3 function in Tregs is characterized by the transcriptional regulation of several 
genes important for Treg function, including activating genes such as CTLA4, GITR and CD25 
while inhibiting IL-2, IFN-γ and IL-4.  Previously, our group has shown that FoxP3 enhances 
the HIV-1 LTR through an NF-κB-dependent mechanism.  Here, we describe a novel function 
for FoxP3 as an inhibitor of cellular deacetylase activity in Jurkat T cells and human Treg 
cells.  FoxP3 inhibition of deacetylase activity is specific for the class I HDAC family member 
HDAC1.  We show that FoxP3 associates with a large molecular weight complex in T cells.  
We also demonstrate that FoxP3 interacts with HDAC1, and the Proline-rich region is 
required for HDAC1 inhibition.  Mutations in the forkhead domain that ablate FoxP3 
function in Tregs also inhibit Foxp3/HDAC1 interaction and consequently ablates FoxP3 
inhibition of HDAC1.  Finally, we demonstrate that knockdown of HDAC1 in T cells inhibits 
FoxP3 regulation of promoter activity.  Thus, FoxP3 modulates gene expression through the 
regulation of HDAC1 activity.      
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Introduction 
 
Regulatory T cells (Tregs) play a crucial role in immune function and homeostasis.  
Originally described as a subset of CD4+ cells expressing high levels of CD25, Tregs are able 
to control autoimmunity induced by neonatal thymectomy (1).  The forkhead winged-helix 
family member FoxP3 is identified as the essential transcription factor necessary for Treg 
development and function (2-4).  Originally described as an inhibitor of cytokines in T cells 
(5), several studies have demonstrated a gene signature of differentially regulated 
promoters associated with FoxP3 expression (6, 7).  Initial studies delineating the molecular 
mechanisms of FoxP3, using the IL-2 promoter as a model promoter, have described 
multiple mechanisms of repression.  FoxP3 interacts with the T cell-specific NFAT 
transcription factor to displace an activating NFAT/AP-1 complex at the IL-2 enhancer (8).  A 
FoxP3/Runx complex has also been shown to be necessary for complete FoxP3-mediated IL-
2 repression at a distal promoter region (9).  More recently, FoxP3 has been shown to 
recruit a chromatin remodeling complex which includes a HAT/HDAC complex (10).  Thus, 
FoxP3 is able to regulate gene expression by modulating factor binding and chromatin 
remodeling. 
Histone deacetylases (HDAC) can be divided into 4 groups.  Class I includes HDAC1-3 
and HDAC8, and class II consists of HDAC4-7 and HDAC9, characterized by conserved 
sequence motifs in the catalytic HDAC domain (11).  The remaining HDAC 11 (class IV) and 
sirtuin-family (class III) are functionally distinct based on their homology (HDAC11) to class I 
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and II HDACs, and NAD+ requirement (sirtuins), respectively.  Histone acetylation is an 
integral component of gene transcription, and HDACs along with other chromatin 
remodeling factors are associated with T cell activation and Treg function.  HDAC inhibitors 
(HDACi) have multiple effects on T cells,  including repression of cytokine gene expression, 
cell cycle arrest and induction of apoptosis (12).  Several groups have shown that TSA blocks 
IL-2 gene expression along with other important inflammatory cytokine (12, 13).  The role of 
HDACs in Treg function is even more revealing.  In vivo TSA administration in mice increases 
Treg numbers and enhances their intrinsic suppressive activity (14).  Promoters regulated by 
FoxP3 binding have an enhanced or reduced level of histone acetylation associated with 
increased or reduced gene expression, respectively (15, 16).  Furthermore, Li et al has 
described a HAT/HDAC complex, Tip60/HDAC7, that is recruited by FoxP3 to the IL-2 
promoter, and its disruption inhibits FoxP3-mediated IL-2 repression.   
The repressive effect on gene expression by class II enzymes has been well 
documented and extensively reviewed (recently by Martin et al. (17)).  Class IIa enzymes 
(HDAC4,5,6,7 and 9) can regulate transcription by direct and indirect mechanisms, but 
multiple studies have questioned the role of the N-terminal deacetylase domain in 
repression.  The deacetylase activity of class IIa enzymes is postulated to originate from 
associated class I HDACs.  In support of this hypothesis, Lahm et al. determined that the 
intrinsic deacetylase activity of class IIa enzymes is 1,000-times less efficient due to a 
conserved histidine residue in the catalytic domain.  Replacement of this residue by 
tyrosine, conserved in class I enzymes, restored class IIa deacetylase function  to class I 
levels (18).   
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In this study we report that FoxP3 regulates promoters similar to HDACi.  We show 
expression of FoxP3 inhibits HDAC activity in Jurkat T cells and primary Tregs.  Importantly, 
we describe a novel role of FoxP3 as an inhibitor of HDAC1-specific deacetylase activity, 
which is important in FoxP3 regulation of gene expression.  This HDAC-dependent inhibitory 
function of FoxP3 requires the N-terminal regulatory domain, and is also inhibited by 
forkhead mutations that block FoxP3 function.  Finally, knockdown of HDAC1 alters FoxP3 
regulation of IL-2 and HIV-1 LTR activity.  This new activity of FoxP3 gives us insight into the 
complex mechanisms of FoxP3-mediated gene regulation.       
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Results  
 
FoxP3 modulates gene expression via HDAC-related mechanisms.  It is well 
established that FoxP3 can repress the IL-2 promoter, and previous work from our lab 
demonstrated FoxP3 enhances HIV-1 gene expression (16).  Interestingly, HDAC inhibitors 
also enhance HIV LTR expression and inhibit IL-2.  We therefore wanted to determine the 
mechanism of FoxP3 repression or activation of targeted promoters in the presence of 
HDACi.  Jurkat cells transduced with control vector or FoxP3 (>90% efficiency by GFP 
expression) were infected with VSV-g pseudotyped HIV-1 NL4-luciferase virus.  Infected cells 
were either unstimulated or activated with plate bound CD3 and CD28.  Treatment of these 
cells 24 hours post infection with the HDAC inhibitor TSA resulted in a 6 fold increase in HIV-
1 gene expression in unstimulated or CD3/CD28 stimulated control cells (Fig 3.1A).  FoxP3 
expressing cells had enhanced LTR expression compared to control cells with or without 
activation, but TSA addition was unable to enhance LTR expression.  We next determined 
the effect of HDACi on FoxP3 repression of IL-2.  Jurkat T cells were transfected with IL-2 
luciferase expressing plasmid in the presence or absence of TSA.  FoxP3 inhibited the IL-2 
promoter by 2-3 fold, and TSA similarly inhibited IL-2 promoter.  Addition of both TSA and 
FoxP3 increased additively repression of IL-2 (Fig. 3.1B).  To further this finding to the 
endogenous IL-2 promoter, Jurkat cells were transduced with vector or FoxP3 retrovirus and 
stimulated with PMA and Ionomycin for 16 hours in the presence or absence of TSA.  TSA 
inhibited IL-2 expression 4 fold, to similar levels seen with Foxp3 expression, and FoxP3 in 
the presence of TSA repressed IL-2 (Fig. 3.1B).  Therefore the activation of LTR or inhibition 
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of IL-2 by FoxP3 and TSA was through the same pathway and we proposed that FoxP3 might 
act like an HDACi.   
 
Reduced class I HDAC activity in human T cells expressing FoxP3.  Since FoxP3 
works similar to HDACi in human T cells, we next wanted to determine the effect of FoxP3 
on global HDAC deacetylase activity.  Utilizing a live cell permeable HDAC substrate, we 
were able to determine the intracellular HDAC activity of cells in culture.  FoxP3 expressed 
by retroviral transduction in Jurkat cells decreased global HDAC activity, approximately 30-
50% reduction as assessed by HDAC assay (Fig. 3.2B).  Addition of TSA completely reduced 
HDAC activity to equivalent background levels.  Similarly with nuclear lysates, HDAC activity 
was decreased in Foxp3 transduced Jurkat cells compared to vector control when 
normalized to total protein (Fig. S3.1).  We next wanted to determine if HDAC activity is 
lower in primary Treg cells.  Human CD4+ T cells purified from whole blood were sorted into 
CD4+CD25- (Teff cells) and CD4+CD25+ (Treg cells) populations and activated by plate-
bound CD3 and CD28 antibody stimulation.  The relative HDAC activity in Tregs cells was 
reduced by ~25% compared to CD4+CD25- population (Fig. 3.2B).  FoxP3 is a member of the 
Foxp subfamily of Forkhead family transcriptional regulators.  In order to determine if the 
HDAC inhibitory function of FoxP3 was also found in other family members, FoxP2 and 
FoxP4 were expressed in Jurkat T cells by retroviral transduction.  When total HDAC activity 
was assayed, FoxP2 and FoxP4 also reduced global HDAC levels by 40% and 25%, 
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respectively (Fig. 3.3).  Thus, other Forkhead P family members also have HDAC inhibition 
activity.   
 
FoxP3 inhibits HDAC1 activity.  We next wanted to determine the specific HDAC 
inhibited by FoxP3.  Since class I HDACs are responsible for most , if not all, of the 
intracellular HDAC enzymatic activity (18), we overexpressed FoxP3 and various class I 
(HDAC1, 2 and 3) and class II HDACs (HDAC4) in 293T cells.  Flag-tagged HDAC1, 2, 3 and 
HDAC4 were immunoprecipitated from equal amounts of nuclear lysates in the presence or 
absence of FoxP3.  HDAC deacetylase activity in the precipitated complex was assessed 
following addition of an acetylated substrate specific for HDACs.  FoxP3 was able to 
efficiently inhibit HDAC 1 but not HDAC 2-4 (Fig. 3.4A).  To ensure the difference was not 
due to HDAC expression or immunoprecipitation, the IP’ed HDAC1-4 proteins were 
measured by western blot analysis and both HDAC and FoxP3 expression levels were similar 
between transfections (Fig. 3.4B inset).  To ensure that inhibition of HDAC1 occurred in a 
more physiologically relevant context, FoxP3-dependent HDAC inhibition was assayed in 
Jurkat cells over-expressing HDAC1 by retroviral transduction.  HDAC1 expression increased 
the cellular HDAC activity above vector control, and FoxP3 was also able to inhibit HDAC1-
specific deacetylase activity (Fig. 3.4B).  As a control, we show that nuclear levels of HDAC1 
in Jurkat cells were not affected by FoxP3 expression (Fig. 3.4C).  To define the functional 
domain involved in the HDAC inhibition activity of FoxP3, a number of FoxP3 mutants with 
deletions and point mutations were tested.  Flag-tagged HDAC1 immunoprecipitated with 
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FoxP3 lacking the N-terminal proline-rich regulatory domain (mychFP3-C) had impaired 
HDAC1 inhibition, thus the forkhead, leucine zipper and zinc finger domains are not 
sufficient to inhibit HDAC1 deacetylase activity (Fig. 3.4D).  Interestingly, the WWRR FoxP3 
mutant, which is unable to repress IL-2 or reprogram Treg cells (8), also has impaired HDAC1 
inhibition activity when over-expressed in 293T cells (Fig. 3.4D).  As a control, the FoxP3 
mutant WRR which has slightly reduced function in vivo compared to wild type FoxP3, also 
inhibited HDAC activity, but slightly lower than wild type FoxP3 (Fig. 3.4D).  Similarly, when 
the WWRR mutant was over-expressed in Jurkat T cells, it had drastically reduced HDAC-
inhibitory function compared to wild type FoxP3 (Fig. 3.4E).  Therefore, as in IL-2 repression 
and Treg reprogramming, both the N-terminal regulatory region and a functional forkhead 
domain of FoxP3 are required for HDAC1 inhibition by FoxP3.   
There are several mechanisms of HDAC regulation, including gene expression, 
posttranslational modification and association with a multi-subunit protein complex.  We 
measured co-segregation of HDAC1 and FoxP3 by size-fractionation.  As reported previously 
by Li et al., FoxP3 fractionates into high and low molecular weight complexes (19, 20).  
Similarly, we see FoxP3 fractionate into high molecular weight fractions (Fig. S3.2).  HDAC1 
is found in similar weight fractions as FoxP3, along with other chromatin remodeling factors 
(data not shown) consistent with Li et al.  We next wanted to determine if FoxP3 interacts 
with HDAC1 to regulate its deacetylase activity.  293T cells transfected with myc-tagged 
FoxP3 with or without flag-tagged HDAC1 were immunoprecipitated with Flag M2 antibody.  
FoxP3 pulldown was enriched when HDAC1 and FoxP3 were coexpressed (Fig. 3.5A, left 
panel).  In Jurkat T cells transduced with myc-FoxP3, endogenous HDAC1 was also co-IP’ed 
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with FoxP3 (Fig. 3.5A, right panel).  In order to map the domain of FoxP3 required for 
HDAC1 interaction, 293T cells were transfected with myc-FoxP3 or successive N-terminal 
truncation mutants of FoxP3 deleting the proline-rich region (FoxP3-C), the zinc-finger 
(FoxP3-LZ-FKH), and all domains up to the forkhead (FoxP3-FKH).  HDAC1 associated with 
FoxP3 through the forkhead domain and importantly, the FoxP3 mutant WWRR did not bind 
HDAC1 (Fig. 3.5B).  The fact that the WWRR mutant is unable to associate with HDAC1 and 
is unable to inhibit HDAC1 activity suggests that the interaction of HDAC1 with FoxP3 is 
important for FoxP3-mediated HDAC inhibition. 
      
HDAC1 is required for FoxP3 inhibition of IL-2.  In order to translate FoxP3 inhibition 
of HDAC1 to gene regulation, we utilized validated siRNA from Dharmacon specific to 
HDAC1 in IL-2 luciferase assays.  Jurkat cells were transiently transfected with a scrambled 
siRNA or HDAC1 siRNA in the presence or absence of FoxP3.  In accordance of TSA inhibition 
of IL-2, IL-2-driven luciferase levels were reduced when HDAC1 was knocked down, 
suggesting that HDAC1 is an important target in HDACi-mediated IL-2 suppression (Fig. 
3.6A).  Interestingly, reduced HDAC1 expression in T cells also decreased the relative 
inhibition of IL-2 expression by FoxP3 (from 4.5x to 2.5x), while FoxP3 repression was 
unaffected by HDAC1 knockdown (Fig. 3.6A and data not shown).  To ensure that HDAC1 
inhibition was also occurring at the endogenous IL-2 promoter, Jurkat T cells stably 
expressing HDAC1 shRNA from a lentivirus were activated with PMA and ionomycin, and IL-
2 secreted into the media was measured by ELISA.  Under conditions where HDAC1 levels 
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were knockdown ~40% by protein level determination, expression of IL-2 was inhibited by 
40% compared to a nonspecific shRNA control cells, similar to the effect seen in transient 
transfection assays (Fig. 3.5B).  Under the same condition, FoxP3-specific activity was also 
reduced by ~40% compared to non-specific shRNA control (Fig. 3.6B).  We next determined 
the role of HDAC1 in the regulation of FoxP3-mediated activation of HIV-1 LTR.  HDAC1 
knockdown reduced FoxP3 activity at the LTR by approximately 2 fold (Fig. 3.6C).  Thus, 
FoxP3-mediated regulation of the LTR and IL-2 promoters goes through an HDAC1-specific 
activity. 
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Discussion  
 
We have previously determined that FoxP3 acts as a transcriptional activator of HIV-
1 while suppressing the IL-2 promoter in human T cells.  We report that FoxP3 and HDAC 
inhibitors function through similar pathways to modulate gene expression, and we found 
that FoxP3 inhibited HDAC activity in human Treg cells.  Ectopic expression of FoxP3 in 
Jurkat T cells resulted in decreased intracellular HDAC activity, and CD4+CD25+ Tregs 
isolated from human PBMC’s also had lower levels of HDAC activity compared to 
CD4+CD25- T cells.  We show that HDAC1 is the main target for inhibition by FoxP3, and that 
both the N-terminal proline-rich region and the forkhead domain required for FoxP3 activity 
in vivo were also required for HDAC1 inhibition.  We further demonstrate that FoxP3 exists 
in high molecular weight complexes and co-fractionates with HDAC1.  FoxP3 interacts with 
HDAC1 and this association requires the Forkhead-domain.  To give this activity biological 
relevance, we show that the Forkhead mutant (Foxp3-WWRR) lacking FoxP3 function was 
unable to bind to and inhibit HDAC1.  Finally, we report a previous unknown function for 
HDAC1 in IL-2 activation.  shRNA knockdown of HDAC1 inhibited endogenous IL-2 
expression and reduced the relative inhibition of IL-2 by FoxP3.  Thus, FoxP3 acts like an 
HDAC inhibitor to modulate gene expression in T cells via inhibition of HDAC1 activity.  
HDAC inhibitors (HDACi) have been extensively studied as anticancer agents.  
Several studies have demonstrated the effect of HDACi on cell cycle progression and 
apoptosis of tumor cells, but the role of HDACi in vivo may be broader yet.  Administration 
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of HDACi reduces the severity of graft-versus-host disease in mice (21), while HDACi reduces 
the in vivo levels of proinflammatory cytokines INF-γ, TNF-α and IL-1-β (22), which are 
implicated in GVHD disease progression (23).  Still others have shown that addition of the 
HDACi TSA results in a decrease in IL-2 gene expression in T cells (12, 13), although the 
specific HDAC targeted in these studies was not identified.  Here, we demonstrate that 
HDAC1 is required for IL-2 transcription and is the likely target of TSA in these studies. 
HDACs play a central role in chromatin remodeling and transcriptional regulation.  
Recently, Tao et al. implicated Tregs as an immunologically relevant target of in vivo HDACi 
activity.  SAHA directly affected Foxp3+ Treg cells by increasing the in vivo cellularity and, 
more intriguingly, enhancing Treg suppressive function.  The mechanism of enhanced 
suppressive activity is unknown, although HDACi increased the levels of Foxp3 and the cell 
surface expression of Treg-associated inhibitory molecules such as GITR and CTLA-4 (14).  
Also, HDACi was shown to enhance the acetylation of FoxP3, and mutation of lysine 
residues abrogated FoxP3 function.  Although we were unable to demonstrate FoxP3 
acetylation (data not shown) it would be interesting to determine if FoxP3 inhibition of 
HDAC1, or HDAC1 knockdown itself, can lead to enhanced FoxP3 acetylation and activity.  
To date the only known HDACs associated with FoxP3 function are HDAC7 and 
HDAC9.  Li et al. described a mechanism wherein a HAT/ HDAC complex including 
Foxp3/Tip60/ HDAC7 is required for IL-2 repression (10).  HDAC9-/- mice have Treg cells that 
are more suppressive, pointing towards a role of class II HDACs in Treg function (14).  Unlike 
our results, Hancock et al. demonstrated that total levels of HDAC activity in Treg cells was 
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increased compared to CD4+25- cells, explaining that HDAC9 transcript levels were 
increased while expression of all other class I and class II HDACs were unchanged.  One 
explanation for this discrepancy could be murine versus human T cells used in the two 
studies.   It is also unclear at what point following in vitro activation the HDAC levels were 
assayed.  Interestingly, a recent paper showed that intrinsic HDAC deacetylase activity 
between class I (HDAC 1, 2, 3 and 8) and class IIa (HDAC4,5,7 and 9) differed by 1,000 fold, 
pointing to a single amino acid difference in the HDAC catalytic domain between these two 
classes (18).  Thus, most of the deacetylase activity of class II HDACs can be attributed to 
associated class I HDACs.  With this in mind, it will be important to determine the possible 
role of class II enzymes in association with class I enzymes in FoxP3-mediated gene 
regulation. 
How FoxP3 inhibits HDAC1 activity is unclear.  Only a few reports have been 
published on viral proteins targeting HDACs.  Adenovirus early proteins bind to and inhibit 
several HDACs following infection (24-26).  HDACs are regulated by posttranslational 
modification, association with multisubunit complexes, and cofactor availability (27). Unlike 
Class IIa HDACs, which are regulated by shuttling between the cytoplasm and the nucleus, 
class I HDACs are predominantly nuclear.  Studies have shown that HDAC1 is constitutively 
phosphorylated in vivo, although mutation of specific phosphorylated serines had little 
consequence on intrinsic deacetylase activity in vitro.  Since the protein levels of HDAC1 are 
unchanged upon FoxP3 expression (Fig. 3.4C), transcriptional regulation of HDAC1 by Foxp3 
can be ruled out.  FoxP3 is associated with a large molecular weight complex that includes 
Brg-1 and MBD3, components of the SWI/SNF and Mi2/NuRD complex respectively (19, 20).  
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The Mi-2/NuRD complex contains HDAC1 and HDAC2, and Foxp3 is found in a similar high 
molecular weight complex as HDAC1 (Fig. S3.2).  FoxP3 did not seem to alter HDAC1 
association with these multi-subunit complexes (unpublished results).  Interestingly, HDAC1 
itself can be regulated by acetylation.  A HAT/HDAC complex containing  p300 and HDAC1 
occurs in the nucleus, and HDAC1 is acetylated by p300 resulting in decreased HDAC1 
enzymatic activity (28).  FoxP3 has previously been shown to associated with p300 by 
immunoprecipitation (29), and the ability of FoxP3 to regulate HDAC1 by acetylation or 
other modification will be of future interest.   
The downstream target of this reduced HDAC1 activity in Treg cells is unclear.  FoxP3 
binding to and regulation of targeted promoters is associated with changes in histone 
acetylation (15, 16).  A simple model wherein FoxP3 recruits HAT or HDAC complexes to 
enhance or inhibit acetylation and promoter activity would explain this finding.   FoxP3 
inhibition of HDAC1 is likely one of many mechanisms of FoxP3-mediated gene regulation.  
For instance, although TSA inhibits IL-2, CD25 expression levels is relatively unchanged by 
TSA in non-Treg cells (12).  HDACs are also known to regulate gene expression through 
deacetylation of non-histone proteins (30, 31).  Previous reports have shown that HDACi 
repression of IL-2 is associated with inhibition of NF-κB activation in Jurkat cells (13).  FoxP3 
inhibition of HDAC1 could lead to reduced NF-κB activity and thus reduced IL-2 expression.  
Conversely, our previous data demonstrates that Foxp3 enhances HIV-1 LTR through an NF-
κB-dependent mechanism (16).  TSA enhances HIV-1 LTR by both histone and non-histone 
acetylation-dependent mechanisms.  TSA has been shown to relieve LTR repression by 
acetylation of histones and “relaxing” the chromatin to enhance gene expression (32-34).  
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Alternatively, TSA activation of the LTR requires the NF-κB sequences, pointing toward 
transcription factor-dependent enhancement.  FoxP3 may inhibit HDAC1 to modulate the 
activity of NF-κB in T cells.  Several groups have shown that HDACi can both activate (35, 36) 
and repress (13, 37-39) NF-κB activity depending on the cell type and the promoter 
environment.  Therefore, FoxP3 inhibition of HDAC1 might play a role in regulation of 
transcription factor activity, as well as in histone acetylation and chromatin remodeling.        
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Materials and Methods 
 
Plasmids, antibodies and cells.  FoxP3 was cloned into the HSPG retrovirus vector as 
previously described (40).  FoxP3 deletion mutants were described previously (16).  FoxP3 
mutants WRR and WWRR were a obtained from Ajana Rao and described previously (8).  
Human Foxp2 and Foxp4 were obtained from (   ), myc-tagged and subsequently cloned into 
HSPG vector.  Jurkat cells were maintained in RPMI 1640 (Gibco BRL), 293T cells were 
maintained in DMEM and primary human T cells were maintained in Iscoves MEM, 
supplemented with 10% FBS (Sigma), 2mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml 
Streptomycin.  Primary cells are maintained in 10% FBS supplemented Iscoves MEM (Gibco-
BRL).  CD4+ primary T cells were purified from Ficoll separated PBMC by negative selection 
(>95% purity) (MACS human CD4+ T cell isolation kit) and CD4+CD25+ Regulatory T cells 
were purified by MACS human Regulatory T cells isolation kit (Miltenyi-Biotech, Auburn, 
CA).  T reg cell purity was determined by  anti-human CD25-PE (Miltenyi) and CD4-FITC (BD 
Biosciences) staining and dead cells were gated out by 7AAD (Molecular Probes).  
CD4+CD25+ cell purity was > 95%.  T cells were activated by anti-CD3/CD28 mAb crosslinked 
by plate-bound anti-mouse IgG as previously described (41).  Antibodies used in Western 
Blot include Flag M2 (Sigma), myc monoclonal 9E10 and HDAC1 polyclonal rabbit antibody 
(Santa Cruz).   
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 Retrovirus production and transduction.  293T cells were co-transfected with 
retroviral vector, VSV-G and gag/pol containing plasmids as previously described (40).  For 
production of single cycle HIV-Luc reporter virus, 293T cells were transfected with VSV-G 
and HIV-Luc plasmids by Effectene (Qiagen, Valencia, CA).  For retroviral transduction, 
Jurkat cells were spin-inoculated with HSPG vector control or FoxP3 retrovirus to >95% 
efficiency as measured by GFP expression.   
 
 Transfection of Jurkat T cells and luciferase assay.  Jurkat cells were transfected by 
electroporation.  Briefly, 1x10^6 cells were incubated with 15ug empty vector or Foxp3 and 
1ug IL-2 luciferase plasmid along with 500ng of a control GFP plasmid.  24 hours post 
transfection, Jurkat cells were activated with PMA (25ng/ml) and Ionomycin (1um) for 24 
hours.  Cells were lysed in 1x reporter lysis buffer (promega) and luciferase expression was 
determined by Luciferase Assay System (Promega).  Luciferase readings were normalized to 
cell number and % GFP expression for every sample by Guava.  Experiments were done in 
triplicates and repeated at least three times. 
 
 293T cell transfection, Immunoprecipitation and Western Blot.  293T cells were 
transfected using Effectene transfection reagent (Qiagen) per manufacturer 
recommendations.  Cells were fractionated into cytoplasmic and nuclear lysates and 
quantitated by BCA protein assay kit (Pierce).  500ug nuclear lysates were incubated 
overnight with 2ug Flag antibody (Sigma) followed by Protein A bead incubation.  For HDAC 
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assay, beads containing immunoprecipitated complex were washed 4X with PBS and HDAC 
activity was analyzed by Flour De Lys HDAC assay as described below.  For IP-western, beads 
were washed in modified RIPA buffer and subject to SDS-page followed by transfer to PVDF 
membrane and visualization by Western Blot.   FoxP3 was probed with an anti-FoxP3 
antiserum (42) followed by secondary α-rabbit–IgG–HRP (1:10,000) (Amersham 
Biosciences) and visualized by ECL (Amersham
 
Biosciences).    
 
Gel Filtration Chromatography.  Nuclear lysates isolated from 293T cells were 
filtered through Ultrafree-MC 0.22μm columns prior to chromatography.  0.5 mg of total 
protein was run on a Superose 6 10/300GL (Amersham Bioscience) gel filtration column 
using a Duoflow chromatography system (Bio-Rad) in PBS with a flowrate of 0.3ml/min.  
Fractions were collected in 2ml aliquots and subjected to analysis by Western blot. 
 
HDAC Flourimetric Cellular Activity Assay.  1x10^5 Jurkat E6.1 cells were incubated 
with Flour de lys intracellular HDAC substrate (Biomol, Plymouth Meeting, PA) for 1 hour at 
37oC.  Cells were lysed per manufacturer’s protocol and Fluorescence was measured at 
excitation 350 and emission 460 on a Fluostar plate reader.  For HDAC activity of 
immunoprecipitated complex, 20ul agarose beads are incubate with HDAC substrate in 
HDAC assay buffer for 30 minutes at 37oC and developed per manufacturer 
recommendation.  Equal bead/Immunoprecipitated HDAC complex is visualized by Western 
Blot.  For primary cell HDAC assay, cells stimulated for 3 days as described above were 
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assayed under similar conditions as Jurkat T cells.  Experiments were done in triplicate and 
are representative of at least 2 independent experiments. 
 
IL-2 measurement by ELISA.  Jurkat T cells transduced as above were cultured at 
5x105 cells/ml and stimulated with PMA (25ng/ml) and Ionomycin (1uM) for 18 hours.  
Supernatants were collected and secreted IL-2 was quantitated by the Human IL-2 ELISA kit 
per manufacture’s protocol (BD Biosciences, San Diego, CA).  Experiments were done in 
triplicate with 2-3 independent experiments. 
 
Statistical analysis.  For statistical analysis, a two-tailed Student t-test was employed 
where P<0.05 was considered significant. 
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Figure 3.1. FoxP3 modulates gene expression similar to TSA.   
(A) HIV-1 activation by FoxP3 is insensitive to TSA.  Jurkat cells transduced with empty vector or 
FoxP3 are infected with VSV-g pseudotyped HIV-1 NL4-luciferase reporter virus.  24 hours post 
infection, unstimulated or CD3/CD28 stimulated cells are treated with mock or 200nM TSA for 24 
hours.  (B) FoxP3 inhibits IL-2 similar to TSA.  Jurkat cells are transfected with empty vector or FoxP3 
and treated with 200uM TSA for 24 hours.  Cells are lysed and luciferase is determined.   Data 
represents multiple experiments done in triplicate. 
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Figure 3.2. FoxP3 inhibits global HDAC activity in human T cells.   
(A)  Primary human effector T cells (CD4+ CD25-) and Treg cells (CD4+ CD25+) sorted from PBMC’s 
are activated by plate bound CD3/CD28 .  Live cells are cultured with HDAC substrate for 2 hours .  
Total cellular HDAC activity is represented at % HDAC inhibition compared to CD4+ CD25- cells.  (B)  
Jurkat cells transduced with vector or FoxP3 were cultured with cell permeable HDAC substrate.  
Cells were lysed and HDAC activity was assessed by fluorometric analysis with the Flour De Lys Assay 
as described in material and methods.   Data are representative of multiple experiments done in 
triplicate.  
 
 
 
 
 
 
 113 
 
 
 
Figure 3.3.  Other forkhead family members inhibit HDAC activity.   
FoxP2 and FoxP4 inhibit HDAC activity.  Jurkat T cells transduced with vector or myc-tagged 
forkhead family members show reduced HDAC activity by fluorescence deacetylation activity.  Equal 
numbers of cells were incubated 1 hour with fluorescent cell permeable deacetylase substrate and 
assayed for intracellular deacetylase activity.  Experiment done in triplicate.  
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Figure 3.4.  N-terminus and Forkhead domains of FoxP3 are required to inhibit HDAC1 deacetylase 
activity.   
(A) FoxP3 inhibits HDAC1 activity.  Flag tagged HDAC1-4 are cotransfected into 293T cells with vector 
or FoxP3.  HDAC1 activity is specifically inhibited by Foxp3 coexpression.  (B) FoxP3 inhibits HDAC 1 
in vivo.  Jurkat cells transduced with vector or Foxp3 in the presence or absence of HDAC1 
overexpression were analyzed for HDAC activity.  (C)  HDAC1 levels are unchanged by FoxP3.  
Nuclear lysates of Jurkats transduced with vector or Foxp3 are assayed for HDAC1 protein levels by 
western blot.  10ug nuclear lysates are subject to western blot, and probed for HDAC1 and PARP.  
(D)  N-terminus and Forkhead domain of FoxP3 are required for HDAC1 inhibition.  Foxp3 deletion 
mutants and point mutants that are unable to inhibit IL-2 gene expression are cotransfected with 
Flag tagged HDAC1, and HDAC1 deacetylase activity is measured by fluorescence. Data 
representative of multiple Immunoprecipitations. (E)   FoxP3 mutant lacking repressive ability are 
unable to inhibit HDAC activity.  Foxp3 and WWRR transduced Jurkat T cells are incubated with cell 
permeable HDAC substrate and assayed for HDAC activity.       
 
 
 
 
 115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116 
 
 
 
 
Figure 3.5.  FoxP3 interacts with HDAC1.  
(A)  293T cells cotransfected with flag-HDAC1 and myc-tagged FoxP3 were Immunoprecipitated with 
anti-Flag antibody and washed under low stringent conditions (Left) while Jurkat cells transduced 
with FoxP3 were Immunoprecipitated with myc9E10 antibody and probed for endogenous HDAC1 
(Right).  (B)  Forkhead mutation ablates Foxp3:HDAC1 interaction.  293T cells were transfected with 
myc-FoxP3 deletion mutants and Flag-HDAC1.  HDAC1 was immunoprecipitated with anti-Flag M2 
antibody and visualized by western blot.  
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Figure 3.6.  HDAC1shRNA reduces Foxp3 activity at the IL-2 and HIV-1 LTR promoters.   
(A)  Jurkat T cells were transfected with siRNA targeted to HDAC1 or a scrambled siRNA as a control, 
and cotransfected with IL-2-luciferase plasmid.  24 hours post transfection, T cells were activated 
with PMA/Ionomycin.  48 hours post transfection cells were lysed and luciferase activity was 
measured.  Activity is normalized to GFP expressing cells.  (B)  Endogenous IL-2 expression was 
measured in Jurkat T cells stably expressing shRNA specific for HDAC1 or a non-specific shRNA (NS) 
transduced with vector or Foxp3 expressing retrovirus.  IL-2 secreted into the media was detected 
by ELISA. (Inset) Western blot showing knockdown of endogenous HDAC1 in stably transduced 
Jurkat T cells.  (C)  Similar Jurkat T cells transduced with shHDAC1 or shNS lentivirus in the presence 
or absence of FoxP3 were infected with NL-4 luciferase virus and gene expression was measured my 
luciferase expression.  Results shown are representative experiments done in triplicate.  * p<.05, ** 
p<.005 using student t-test.  
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Figure S3.1. HDAC Deacetylase activity in nuclear lysates of Jurkat T cells.   
Jurkat T cells transduced with empty vector or FoxP3 expressing retrovirus are separated into 
nuclear and cytoplasmic fractions.  Equal volume of protein was resuspended in HDAC assay buffer 
and HDAC activity was measured using a fluorometer.   
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         ~670 KDa                                                ~160 KDa 
Figure S3.2.  FoxP3 and HDAC1 co-fractionate in a high molecular weight complex.   
293T cells were cotransfected with FoxP3 and HDAC1.  Nuclear lysates were separated and 
fractionated by size-exclusion gel filtration chromatography column and fractions were resolved on 
a SDS gel.  Antibodies for myc (FoxP3), HDAC1 and Mi-2β were used for analysis by immunoblotting.   
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Abstract 
 
 IL-2 plays a critical role in T cell proliferation and survival and is rapidly induced 
following T cell receptor (TCR) engagement.  The current model of transcription initiation at 
the IL-2 promoter includes a rapid loss of histones at the proximal promoter within 2 hours 
of stimulation, followed by recruitment of transcription factors required for optimal gene 
expression.  Little is known about the mechanism of nucleosome remodeling at the IL-2 
promoter, but there is a clear requirement for chromatin remodeling factors in this process.  
Here, we demonstrate that FoxP3, a member of the forkhead winged-helix family, co-
fractionates with a high molecular weight complex that includes the ATP-dependent 
nucleosome remodeler Mi-2β.  FoxP3 is interacts with Mi-2β in T cells, and this interaction 
requires the zinc finger domain of Foxp3.  Using chromatin immunoprecipitation, we 
demonstrate that Mi-2β is bound to the IL-2 proximal promoter in unstimulated cells, and 
remains associated with the promoter following T cell activation.  Interestingly, FoxP3 
expression is associated with decreased Mi-2β binding to the IL-2 promoter.  Knockdown of 
Mi-2β by shRNA inhibits IL-2 transcriptional activity from a proximal promoter, suggesting a 
role for Mi-2β as a factor required for IL-2 activation.  Thus, we are the first to report a role 
for an ATP-dependent nucleosome remodeling factor in the activation, and FoxP3-mediated 
repression, of the IL-2 promoter.  
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Introduction 
 
In the immune system, the role of CD4+CD25+ regulatory T cells (Treg) is central to 
maintaining self tolerance and immune balance.  The hallmark of Treg cells is a lack of IL-2 
gene expression and hypo-proliferation in vitro (1, 2), the former a cytokine critical for T cell 
activation and proliferation.  T cell activation through TCR engagement results in a signal 
transduction cascade resulting in activation of a broad range of transcription factors 
required for robust proliferation.  Initially, an ~300bp region upstream of the transcriptional 
start site was deemed sufficient for IL-2 activation in the cloned human T cell line Jurkat (3, 
4).  This promoter/enhancer region contains binding sites for key transcription factors 
required for optimal IL-2 expression, namely AP-1, NFAT and NF-κB among others (5).   
Rapid induction of IL-2 upon antigen stimulation requires a coordinated effort of 
transcription factor binding in a large enhanceosome-like complex (6, 7).  Preceded by this is 
a requirement for chromatin modification resulting in changes in chromatin structure across 
the IL-2 promoter.  Several studies have shown that in both mice and human naïve T cells, 
the proximal promoter is inaccessible to digestion by DNase 1 or restriction enzymes.  
Immediately following stimulation, chromatin accessibility to DNase appears, suggesting a 
role of chromatin remodeling (5, 8-10), and later studies described a positioned nucleosome 
in the promoter/enhancer that disassembles following T cell activation (11, 12).  
Interestingly, Su et al. demonstrated that murine Treg cells maintained a relative 
inaccessibility to MNase digestion at the IL-2 promoter following activation, and therefore 
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failed to undergo chromatin remodeling (13).  Thus, factors permitting chromatin changes 
are important for complete IL-2 gene expression in T cells and Treg cells.  
In eukaryotic cells, mechanisms are in place to repress transcription of genes until an 
external or internal response causes gene activation.  Histone modifying enzymes and also 
ATP-dependent chromatin modifying complexes play a crucial role in unraveling or relaxing 
tightly bound chromatin to allow access to transcription factors (14-17).  Covalent 
modifications of core histone tails include site-specific acetylation, phosphorylation, 
ubiquitination and methylation (15, 18, 19).  While covalent modifications can change the 
chromatin structure at promoters, they are not sufficient to promote histone displacement 
and therefore require ATP-dependent chromatin remodeling enzymes.   
Two of the most widely studied chromatin remodeling complexes in eukaryotic cells 
are the SWI/SNF and Mi-2/NuRD complexes.  The NuRD complex was the first complex to 
contain both nucleosome remodeling and histone deacetylase functions, linking these two 
important chromatin remodeling activities.  The multisubunit complex  contains a 
chromatin remodeling ATPase, Mi-2β, along with HDAC1 and HDAC2 (20-23).  Since this 
large molecular weight complex contains deacetylase activity, the Mi-2/NuRD complex was 
implicated in gene repression.  Several studies described transcription factors that associate 
with the Mi-2/NuRD complex and target this complex to specific promoters to repress 
transcription, such as ikaros and Bcl-6 (24, 25).  Despite strong data supporting the role of 
Mi-2β in repression, Williams et al. described a function for Mi-2β as a positive regulator of 
CD4 gene expression in T cell development.  In this study, Mi-2β regulated CD4 promoter by 
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recruiting the histone acetyltransferase (HAT) p300 to enhance transcription.  Still, others 
have shown an association of Mi-2β with RET Finger Protein (RFP) and Brg1 biochemically, 
resulting in either repression or activation of a targeted promoter, respectively (26).  Thus, 
ATP-dependent chromatin remodeling factors are required for differential regulation of 
gene transcription by multiple mechanisms. 
The mechanism of gene regulation by FoxP3 in Treg cells has been of great interest 
in the past decade.  FoxP3 expression in T cells results in both upregulation and repression 
of several genes in Treg cells and is thought to be a lineage specific factor (27-30).  
Mechanistically, FoxP3 has been shown to repress or activate genes through regulation of 
transcription factors.  NFAT and NF-κB transactivation function is regulated by FoxP3 (31-
34), and Wu et al. have shown that FoxP3 inhibits the binding of NFAT/AP-1 at the promoter 
enhancer of IL-2 (32).  Still others have shown an association of FoxP3 targeted promoters 
with either an increase or decrease in histone acetylation on activated or repressed genes, 
respectively (35).  Interestingly, FoxP3 has been shown to associate with a large molecular 
complex in T cells that includes chromatin modifying factors (36), and Li et al. described a 
HAT/HDAC complex required for FoxP3-mediated IL-2 repression (37).  Therefore, evidence 
for a requirement of chromatin remodeling factors for FoxP3-mediated repression of IL-2 is 
abundant. 
In this report, we define a role for FoxP3 and Mi-2β in IL-2 gene regulation.  We 
demonstrate that Foxp3 and Mi-2β co-fractionate to a high molecular weight complex, and 
that FoxP3 associates with Mi-2β Jurkat T cells and 293 cells, with requires the zinc finger 
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domain of FoxP3 for interaction.  We also demonstrate that FoxP3 protein expression is 
associated with a decrease in Mi-2β binding at the IL-2 promoter by chromatin 
immunoprecipitation.  Conversely, a promoter activated by FoxP3, CD25, has no change or a 
slight increase in Mi-2β binding.  We also define a role for Mi-2β as a factor required for 
optimal activation of IL-2 promoter by shRNA knockdown of Mi-2β.  Thus, we report a 
function for FoxP3 in the regulation of IL-2 through inhibition of chromatin remodeling 
factors required for promoter activation.                                                                                                                                                                                                                            
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Results 
 
FoxP3 co-fractionates with Mi-2β in a high molecular weight complex.  Previous 
studies have implicated FoxP3 as a regulator of transcriptional activity by association with 
high molecular weight complexes.  Namely, Li et al. determined that FoxP3 complexes with 
Brg-1 and MBD3, major components of the SWI/SNF and Mi-2/NuRD complexes (36).  
Previous data from our lab demonstrated FoxP3 associates in human T cells with HDAC1, a 
constituent of the Mi-2/NuRD complex.  We therefore wanted to determine the role Mi-2β 
plays in FoxP3-mediated transcriptional regulation.  293T cells were transfected with myc-
tagged FoxP3 or vector control and nuclear extracts were subjected to size-exclusion 
chromatography (See materials and methods).  FoxP3 eluted in multiple high molecular 
weight fractions, ranging in size from >670 KDa to 400 KDa, and co-fractionated with Mi-2β 
(Fig. 4.1).  Similarly, other NuRD components including MBD2 and HDAC1 were also 
localized in these fractions (Data not shown), pointing to a multi-subunit complex that 
includes FoxP3 and NuRD proteins. 
 
FoxP3 and Mi-2β interact in T cells and 293 cells, and the Zinc-Finger domain of 
FoxP3 is required for binding.  We next wanted to determine if Foxp3 is able to associate 
with endogenous Mi-2β.  293T cells transfected with myc-FoxP3 or vector control plasmid 
were immunoprecipitated with myc antibody 9E10 and probed for the association of 
endogenous Mi-2β.  Similarly, human Jurkat T cells transduced with retrovirus expressing 
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FoxP3 or empty control retrovirus were fractionated and lysed, followed by 
immunoprecipitation with anti-myc antibody.  FoxP3 was able to efficiently bind 
endogenous Mi-2β in 293T cells and Jurkat T cells (Fig. 4.2A).  To determine the domain of 
FoxP3 required to interact with Mi-2β, 293T cells were cotransfected with Flag-Mi-2β and 
myc-tagged N-terminal deletion mutants lacking the N-terminal proline-rich domain (FoxP3-
C) only, lacking the N-terminus and zinc finger domains (FoxP3-LZ-FKH), or FoxP3 containing 
just the forkhead domain (FoxP3-FKH).  Immunoprecipitation of Mi-2β with anti-Flag M2 
antibody was able to co-precipitate full length FoxP3 and the mutant lacking the proline-rich 
region (FoxP3-C), but was unable to interact with FoxP3 lacking the zinc finger domain (Fig. 
4.2B).  Therefore, FoxP3 binds Mi-2β in 293T cells and Jurkat T cells, and the interaction 
requires the zinc finger domain. 
 
Mi-2β occupies the promoter/enhancer region of IL-2, and FoxP3 expression is 
associated with a decrease in Mi-2β binding.  Mi-2β is an ATP-dependent nucleosome 
remodeling factor and therefore functions to modify the chromatin structure at promoters.  
More importantly, Mi-2β is a member of the multi-subunit complex Mi-2/NuRD, which has 
been previously shown to associate with HDACs to repress promoter transcription.  
Previous studies have demonstrated the requirements of ATPase-containing chromatin 
remodeling complexes in the activation and inhibition of gene expression (38).  Therefore 
we wanted to determine the function of Mi-2β at the IL-2 promoter.  We chose to analyze 
the ability of Mi-2β to occupy the enhancer region of the IL-2 promoter by chromatin 
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immunoprecipitation (ChIP) assay.  This region contains the FoxP3/NFAT binding site 
required for IL-2 repression by FoxP3, and is located near a region that undergoes 
nucleosome remodeling following T cell activation (11).  Jurkat cells transduced with 
retrovirus expressing FoxP3 or vector control were lysed and subjected to ChIP analysis 
following various times of stimulation.  Mi-2β was present at the IL-2 proximal promoter in 
unstimulated vector transduced Jurkat cells and maintained association or was slightly 
increased after 6 hours of activation with PMA and Ionomycin.  In FoxP3 expressing cells, 
Mi-2β was significantly reduced at the IL-2 promoter in unstimulated cells and following 
stimulation (Fig. 4.3A).  At a later timepoint, 12 hours post activation, Mi-2β was reduced 2 
fold at the promoter, indicating a requirement for continual Mi-2β binding during 
stimulation (Fig. 4.3B).  Interestingly, the association of another NuRD component, HDAC1, 
was unchanged in FoxP3 expressing cells (Fig. 4.3B), potentially excluding a function for the 
NuRD complex in IL-2 regulation.  Thus, Mi-2β could be functioning in a capacity 
independent of both the NuRD complex and HDAC1, and rather as an activating factor at 
the IL-2 promoter.   
We also wanted to determine the ability of Mi-2β to associate with another 
promoter known to bind FoxP3.  CD25, a promoter that is differentially regulated by Foxp3, 
is enhanced by the expression of FoxP3 in T cells.  Therefore we wanted to determine the 
binding of Mi-2β at a promoter upregulated by FoxP3 in Treg cells.  Under activation 
conditions in which IL-2 is repressed and Mi-2β binding to the promoter is decrease in 
FoxP3 expressing Jurkat T cells, Mi-2β was bound to the CD25 promoter and FoxP3 
expression was associated with no change or a slight enhancement in Mi-2β binding (Fig. 
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4.4).  Thus, Mi-2β association with promoters is differentially regulated in Foxp3 expressing 
T cells. 
 
Knockdown of Mi-2β in human T cells inhibits IL-2 gene expression.  Previous 
studies have alluded to a function of chromatin remodeling factors in the inhibition of IL-2 
gene expression in Treg cells.  Upon CD3 and CD28 stimulation, the IL-2 promoter shifts 
from a closed to an open chromatin conformation as demonstrated by an increase in 
chromatin accessibility micrococcal nuclease accessibility assays, and the accessibility of the 
IL-2 promoter is reduced in Tregs (13).  Several ATP-dependent chromatin remodeling 
factors are located at promoter regulatory regions and are required for relaxing the 
chromatin to allow for transcription factor binding and promoter activation.  The above 
ChIP data points to a possible requirement for Mi-2β in IL-2 gene expression.  Therefore, we 
wanted to determine if Mi-2β is capable of modulating IL-2 activation.  Jurkat T cells were 
transfected with an IL-2-luciferase expression plasmid in the presence of a non-specific 
shRNA (NS) or a Mi-2β-specific shRNA expression plasmid.  Knockdown of Mi-2β inhibited 
the activation of IL-2 promoter expression by 2 fold compared to NS control (Fig. 4.5).  
Therefore, IL-2 requires Mi-2β function for optimal gene expression in T cells.  
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Discussion 
  
In this report we study the interaction of FoxP3 and the chromatin remodeling factor 
Mi-2β in human T cells.  Reported here and previously from the Mark Greene’s group (36) it 
has been shown that FoxP3 protein is found in a low (not described here) and high 
molecular weight complex by fractionation based on size exclusion gel filtration of nuclear 
extracts.  In molecular weight fractions ranging from 420 to >670, FoxP3 co-fractionates 
with the ATP-dependent chromatin remodeling factor Mi-2β.  Importantly, we demonstrate 
a strong interaction between FoxP3 and Mi-2β in both nuclear lysates of transient 
transfected 293T cells and Jurkat T cells expressing FoxP3 by retroviral transduction.  We 
show that this interaction requires the zinc finger domain of FoxP3.  To define the function 
of Mi-2β in T cell activation, we demonstrate that in the presence of FoxP3 protein, Mi-2β 
association with the IL-2 proximal promoter is reduced 2 fold at multiple timepoints 
following strong stimulation with PMA and Ionomycin.  Interestingly, at a promoter that is 
enhanced by FoxP3 expression, CD25, there is a slight increase in Mi-2β binding when FoxP3 
is present.  Finally, knockdown of Mi-2β in Jurkat T cells by transfection resulted in a 
decrease in IL-2 expression by an IL-2 proximal promoter driving luciferase reporter, 
pointing towards a function for Mi-2β in activation of IL-2 transcription. 
 As a model for T cell activation, the IL-2 promoter has been studied extensively.  In 
naïve T cells, the IL-2 promoter is maintained in a compacted, closed chromatin 
conformation.  Following TCR ligation or phorbol stimulation (PMA), the nucleosome 
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spanning the core enhancer on the IL-2 promoter disassociates to allow transcription factor 
binding.  It has been proposed at the IL-2 promoter that nucleosome disassembly following 
activation is maintained for the duration of the external activation signal, and can be 
reversed following the removal of stimuli (11).  A study from the Smale group addressed the 
mechanism of activation of inflammatory response genes in macrophages following LPS 
stimulation.  Two chromatin remodeling complexes, SWI/SNF and Mi-2/NuRD, associated 
with multiple promoters and had antagonistic function.  The SWI/SNF complex was found to 
be constitutively present at the primary response promoters such as Ccl5 and ifnb1(38), and 
studies with IFN-α inducible promoters report a model wherein rapid transcription 
induction is required by the association of bound ATP-dependent chromatin remodeling 
factors (39).  A similar model of promoter occupancy by Mi-2β could occur at the IL-2 
promoter, where the association of Mi-2β ATPase is required for nucleosome disassociation 
and transcription factor binding.  SWI/SNF is bound to primary response promoters in 
macrophage cells prior to activation, although loss of BRG1/BRM by retroviral knockdown 
had no effect on the activation of early primary response genes.  Based on our Mi-2β 
knockdown experiments, it appears that Mi-2β is required for normal activation of IL-2, 
although the exact mechanism will have to be determined.  
 At the present time, it is unclear if the reduction of Mi-2β at the IL-2 promoter 
requires the interaction between FoxP3 and Mi-2β.  One could envision a model where 
FoxP3 protein expression results in the binding of Mi-2β and subsequent removal from the 
IL-2 promoter, thus functioning to actively remove factors from a promoter.  A more 
reasonable model might include a more indirect function of FoxP3.  Promoters that FoxP3 
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binds to and activates, such as CD25, showed a slight increase in Mi-2β association.  FoxP3 
could actively recruit Mi-2β to enhance transcription, redistributing a limited pool of 
chromatin remodeling factors other promoters.  Proper activation of the CD4 gene requires 
a Mi-2β/p300 HAT complex to activate transcription, therefore FoxP3 might recruit an 
activating Mi-2β/HAT complex to promoters that are directly enhanced by FoxP3 
association.   Conversely, FoxP3 might recruit other chromatin modifying factors to the IL-2 
promoter, resulting in displacement of Mi-2β.  This latter model would make the protein-
protein interaction inconsequential with respect to the IL-2 promoter.  Future studies will 
be needed to determine what chromatin modifying complexes are present at the IL-2 
promoter, and if FoxP3 actively recruits a repressive complex.  We have yet to determine 
the effect of Mi-2β on FoxP3 regulation of targeted promoters.  Mi-2β stable knockdown in 
FoxP3 expressing cells will allow us to determine to function of Mi-2β in FoxP3-mediated 
promoter regulation.   
 The functional consequence of the FoxP3/ Mi-2β interaction with respect to Treg 
function has yet to be determined.  The question remains if the suppressive function or in 
vitro proliferation defect relies on the interaction of FoxP3.  Previous reports using a 
conditional Mi-2β knockout in T cells showed a requirement for Mi-2β in CD4 promoter 
regulation.  Interestingly, it was noted that peripheral T cells lacking Mi-2β showed a defect 
in in vitro proliferation, a function that was independent of TCR engagement since PMA and 
ionomycin activation showed similar results as CD3/CD28 engagement.  Thus, the function 
of Mi-2β, and more importantly the FoxP3/ Mi-2β interaction, in Treg hypoproliferation 
should be determined.      
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It is unclear if FoxP3 expression in Jurkat cells will result in the decreased chromatin 
accessibility seen in primary Tregs activated in vitro.  It will be crucial to demonstrate that 
FoxP3 reduces MNase digestion in Jurkat cells, and similarly, if Mi-2β is required for 
chromatin remodeling at the IL-2 promoter.  Whether Mi-2β shRNA-mediated knockdown 
will result in impaired nucleosome remodeling will have to be determined, either by MNase 
digestion activity or assessment of histone acetylation dynamics at the proximal IL-2 
promoter. 
To date, FoxP3 has been shown to interact with proteins ranging from transcription 
factors such as NFAT, NF-κB and Runx1, to chromatin remodeling factors such as the HAT 
Tip60, HDAC1, 7 and HDAC9.  FoxP3 is organized into four structural domains, which 
includes the most N-terminal proline-rich region, zinc finger domain, leucine zipper, and C-
terminal forkhead domain.  The forkhead domain has a clear function in both DNA binding 
and transcription factor interaction, and the N-terminus is required for transcriptional 
regulation.  So far, natural mutations of FoxP3 in IPEX individuals have been found in every 
region but the zinc finger domain.  As a functional domain, the zinc finger and the leucine 
zipper are the minimal requirements for FoxP3 homo- and hetero-multimerization, 
although point mutations that disrupts the zinc finger structure are unable to inhibit 
multimerization (36).  This data along with the lack of natural mutations in this region found 
in IPEX patients makes the role of the zinc finger in FoxP3 function unclear at this time.  
Therefore, this has been the first description of a FoxP3-protein interaction requiring the 
zinc finger.  Future experiments utilizing zinc finger mutations that inhibit the interaction 
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between FoxP3 and Mi-2β will provide insight into the functional importance of this specific 
interaction.     
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Materials and Methods 
 
Plasmids, cell lines and shRNA.  Jurkat cells were maintained in RPMI 1640 (Gibco 
BRL), 293T cells were maintained in DMEM and primary human T cells were maintained in 
Iscoves MEM, supplemented with 10% FBS (Sigma), 2mM L-glutamine, 100 U/ml penicillin, 
and 100P
 Pmg/ml Streptomycin.  Mi-2β shRNA expressed from a lentivirus vector pLKO was 
obtained from Open Biosystems (Open Biosystems).  Foxp3 expressed in HSPG retroviral 
vector was previously described (40).   
 
Gel Filtration Chromatography.  Nuclear lysates isolated from 293T cells were 
filtered through Ultrafree-MC 0.22μm columns prior to chromatography.  0.5 mg of total 
protein was run on a Superose 6 10/300GL (Amersham Bioscience) gel filtration column 
using a Duoflow chromatography system (Bio-Rad) in PBS with a flowrate of 0.3ml/min.  
Fractions were collected in 2ml aliquots and subjected to analysis by western blot. 
 
 Transfection of Jurkat T cells and luciferase assay.  Jurkat cells were transfected by 
electroporation.  Briefly, 1x10^6 cells were incubated with 15ug empty vector or Foxp3 and 
1ug IL-2 luciferase plasmid along with 500ng of a control GFP plasmid.  24 hours post 
transfection, Jurkat cells were activated with PMA (25ng/ml) and Ionomycin (1um) for 24 
hours.  Cells were lysed in 1x reporter lysis buffer (promega) and luciferase expression was 
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determined by Luciferase Assay System (Promega).  Luciferase readings were normalized to 
cell number and % GFP expression for every sample by Guava.  Experiments were done in 
triplicates and repeated at least three times. 
 
 293T cell transfection, Immunoprecipitation and Western Blot.  293T cells were 
transfected using Effectene transfection reagent (Qiagen) per manufacturer 
recommendations.  Cells were fractionated into cytoplasmic and nuclear lysates and 
quantitated by BCA protein assay kit (Pierce).  500ug nuclear lysates were incubated 
overnight with 2ug Flag antibody (Sigma) followed by Protein A bead incubation.  For HDAC 
assay, beads containing immunoprecipitated complex were washed 4X with PBS and HDAC 
activity was analyzed by Flour De Lys HDAC assay as described below.  For IP-western, beads 
were washed in modified RIPA buffer and subject to SDS-page followed by transfer to PVDF 
membrane and visualization by Western Blot.   FoxP3 was probed with an anti-FoxP3 
antiserum (41) followed by secondary α-rabbit–IgG–HRP (1:10,000) (Amersham 
Biosciences) and visualized by ECL (Amersham
 
Biosciences).    
 
ChIP assays.  Jurkat E6.1 cells were transduced with control or FoxP3-expressing 
vectors.  Sonicated chromatin from the Jurkat cells was IP'ed with control IgG (IgG), anti-Mi-
2β (Santa Cruz) or anti-HDAC1 (Ebioscience) and assayed by chromatin immunoprecipitation 
assay kit per manufactures instruction (Upstate, Millipore).  IP’ed chromatin was purified 
using a PCR purification kit (Qiagen) and samples were subject to real-time qPCR analysis by 
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syber green.  The relative Mi-2β binding or HDAC1 binding to the IL-2 enhancer promoter is 
expressed with ratios of ChIP-specific signal divided by signals from control 10% input 
chromatins.  IL-2 promoter was analyzed with the following primers: 5’-cac cta agt gtg tgg 
gct aat gta ac-3’ and 5’-ctg atg act ctt tgg aat ttc ttt aaa cc-3’.  This amplicon spans -226 to -
133 in the human IL-2 promoter and spans the NFAT and Foxp3 binding sites. 
 
Statistical analysis.  For statistical analysis, a two-tailed Student t-test was employed 
where P<0.05 was considered significant. 
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Figure 4.1.  FoxP3 localizes with Mi-2β in a high molecular weight complex in 293T cells.   
293T cells were transfected with myc-tagged human FoxP3, and 48 hours post transfection nuclear 
lysates were isolated.  FoxP3 complexes were size-fractionated by gel filtration columns followed by 
western blot analysis with anti-myc antibody and anti-Mi-2β antibody specific for endogenous Mi-
2β.  
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Figure 4.2.  FoxP3 interacts with Mi-2β, and requires the zinc finger domain.   
(A) Domain organization of Foxp3.  Proline-rich region (PRR), zinc-finger domain (ZF), leucine zipper 
region (LZ) and Forkhead DNA-binding domain (FKH).  (B)  293T cells were transfected with 
mycFoxp3 (Top) or Jurkat T cells were transduced with empty vector or Foxp3 expressing retrovirus 
(Bottom), nuclear lysates were subjected to immunoprecipitation with anti-myc antibody, and 
visualized by western blot against endogenous Mi-2β.  (C) 293T cells were cotransfected with myc-
tagged Foxp3 or a series of N-terminal truncation mutants deleting the proline-rich region (Foxp3-C), 
containing the leucine zipper and forkhead only (Foxp3-LZ-FKH), or containing the forkhead domain 
(Foxp3-FKH) along with flag-tagged Mi-2β.   
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Figure 4.3.  Foxp3 regulates Mi-2β association at the IL-2 promoter in Jurkat T cells. 
 Jurkat T cells are transduced with vector or Foxp3 and mock stimulated or stimulated for 1 or 6 
hours (Left graph) or 12 hours (right graph) with PMA and Ionomycin.  Cells are chemically 
crosslinked, and chromatin is immunoprecipitated with anti-Mi-2 or HDAC1 antibodies.  Enrichment 
of IL-2 proximal promoter is determined by Syber Green quantitative Real-time PCR.  Fold 
enrichment represents signal over IgG.  Samples are measured in triplicates for each experiment. 
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Figure 4.4. Promoters differentially regulated by Foxp3 are associated with differential binding of 
Mi-2β.   
Jurkat T cells transduced with empty vector or Foxp3 are stimulated with PMA and Ionomycin for 12 
hours and relative Mi-2β binding at the IL-2 and CD25 promoters is determined by ChIP assay.  
Samples are normalized to 10% input and fold enrichment over IgG is determined. 
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Figure 4.5.  Mi-2β is required for optimal IL-2 expression in Jurkat T cells.  
 Jurkat T cells are transfected with shRNA lentivirus plasmid containing a control irrelevant GFP 
shRNA or three shRNA plasmids designed against Mi-2β.  Knockdown of Mi-2β in 293T cells is 
demonstrated by western blot against a flag-Mi-2 overexpressed in 293T cells (Left).  IL-2 luciferase 
plasmid is cotransfected with shRNA plasmids in Jurkat T cells and luciferase is determined by 
luciferase assay.  Results are normalized to a GFP reporter for all transfected samples. 
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Conclusions and Future Directions 
 
 
 
 
 
 
 
 
 
 
 
 
 152 
 
Perspective and Scope 
  
While the role of FoxP3 in the biology of Treg cells is currently being scrutinized, it is 
clear that an elaborate and poorly understood landscape of gene regulation and cell 
signaling is required to make a Treg a ‘regulatory cell’.  The fact that T cells can be guided 
into a regulatory phenotype at multiple stages of the T cell life cycle, from development of 
natural Tregs in the thymus to the conversion to adaptive Treg cells in the periphery, 
highlights the importance of this subset of T cells in the grand view of immune regulation.  
Through Microarray technology and ChIP-Chip assays, the profile of gene regulation and 
targets of FoxP3 transcriptional regulation on a genomic scale has been described.  
Comparisons of gene regulation between general T cell activation versus natural or induced 
Tregs have narrowed the scope of gene that are directly modulated upon FoxP3 expression 
in T cells.  Thus, the foundation is in place for determining and characterizing the 
mechanisms of FoxP3 regulation of gene transcription.  The scope of this body of work is to 
do just that, find novel in vivo targets of FoxP3 that are critical for transcriptional regulation.  
Herein, I will summarize findings of novel mechanisms and targets for FoxP3-mediated 
regulation, the implications of these findings, and future experiments and directions to 
further our knowledge of FoxP3 function.        
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Chapter2: FoxP3 enhances HIV-1 LTR through an NF-κB-dependent mechanism. 
 
Findings and Implications 
  
Chapter two highlights a novel function of FoxP3 in the regulation of gene 
expression, namely, the activation of HIV-1 LTR in human T cells.  Here we describe 
disparate regulation of the HIV-1 LTR compared to the well studied and documented IL-2 
gene.  Previous findings at the IL-2 promoter have described a model wherein FoxP3 
regulates promoter activity through modulation of multiple transcription factors.  Initially it 
was shown that FoxP3 can form a complex with NFAT, effectively inhibiting the formation of 
an NFAT/AP-1 complex (1).  More recent data have suggested that FoxP3 is also able to 
negatively regulate AP-1 DNA binding activity without altering protein levels, further 
supporting a role of inhibition of a NFAT/AP-1 complex (2).  FoxP3 is also capable of 
combining with other transcription factors normally required to activate IL-2, as seen with 
the Foxp3/Runx1 complex.  Here we demonstrate the requirement for yet another 
transcription factor, NF-κB, required for FoxP3-mediated activation of HIV-1 LTR.  Knocking 
down NF-κB or ablating the NF-κB binding sites in the LTR completely inhibits FoxP3-
mediated activation.    We describe a model where FoxP3 enhances the binding of NF-κB at 
the LTR, but not the IL-2 promoter as one mechanism of regulation.  Importantly, we 
integrate both modulation of transcription factor binding and histone modifications with 
differential regulation of LTR and IL-2.  We also describe differential regulation of histone 
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acetylation, where FoxP3 repression of IL-2 is associated with decreased acetylated histone 
3, while the LTR activation is associated with an increased in histone acetylation.  Consistent 
with this result, other groups have described an association of Foxp3 activation or inhibition 
of gene expression with increased or decreased acetylated histones, respectively (3). 
 To date, Foxp3 has been shown to directly and indirectly regulate genes and act as 
both an activator and repressor.  Studies using T cell hybridomas lacking or expressing 
Foxp3, or natural Treg cells versus Foxp3- T cells, analyzed on a global scale the promoters 
that were directly bound by Foxp3 (4, 5).  Of note, Foxp3 directly bound only a small 
fraction of the promoters of genes that were differentially regulated upon Foxp3 
expression, revealing both a direct and indirect role of Foxp3 in gene regulation.  
Interestingly, most of the promoters that Foxp3 directly occupied were (i) responsive to TCR 
stimulation, (ii) regulated only upon activation, and (iii) were associated with a NFAT 
binding motif.  This correlates with the fact that most of the Foxp3 responsive genes are 
NFAT-dependent.  Regulation of the HIV-1 LTR by FoxP3 is intriguing for the fact that FoxP3 
enhances LTR independent of NFAT activation, under unstimulated conditions or upon 
CD3/CD28 stimulation, while strong stimulation such as PMA/Ionomycin negates the FoxP3 
effect.  Marson et al. clustered several genes that were differentially regulated +/- Foxp3 
and +/- stimulation, and associated these clusters with Foxp3 promoter occupancy.  
Interestingly, the gene cluster that mirrored Foxp3 regulation of LTR, that is to say genes 
that were activated with and without stimulation in the presence of Foxp3, were associated 
with a lack of Foxp3 promoter binding.  Preliminary data of FoxP3 binding to the HIV-1 LTR 
in 293T cells upon transient transfection  followed by ChIP assay shows that FoxP3 is able to 
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bind the LTR.  Thus, HIV might have adapted the LTR to utilize cellular conditions that are 
optimal for LTR transcription, inconsistent with the functional role of FoxP3 in the 
regulation of stimulus-dependent gene transcription.   
 FoxP3 largely plays a similar role in repression between murine and human Treg 
cells, with one notable difference in the fact that most human T cells activate FoxP3 upon 
antigenic stimulation, whereas murine Foxp3 is expressed only in Treg cells.  Thus, it is 
thought FoxP3 might play a more general role in the control of the T cell receptor response.  
This is supported by the fact that Foxp3 dampens genes that are activated upon TCR 
stimulation.  The ability of HIV-1 LTR to respond to FoxP3 might be a direct adaptation of 
disease pathogenesis and progression.  Currently, the topic of Tregs in HIV disease 
progression has gained considerable attention for the obvious role that Tregs play in T cell 
activation and function.  It is now becoming evident that Treg cells are a direct target of 
HIV-1, SIV and FIV infection (6-8).  Recent analysis of Tregs in SIV infection over time in 
rhesus macaque model versus sooty mangabey model has given us insight into the potential 
role of Tregs in disease progression (9, 10).  Differences in disease progression between the 
‘natural’ SIV hosts (sooty mangabey, African green monkey) and ‘un-natural’ hosts (rhesus 
macaque) highlights the role of overt immune activation as the best predictor of disease 
progression.  The SIV-infected sooty mangabey lacks overt immune-hyperactivation in the 
presence of high viral load, while rhesus macaque show a decline in CD4+ T cells, hyper-
immuneactivation, and disease progression.  In support of the critical role of Treg cells in 
immune-regulation, the differences in Treg dynamics in SIV infection between these two 
monkey models is important.  These studies demonstrate that Treg cells can be depleted in 
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both acute and chronic stage of SIV infection, although discrepancies have been seen in the 
former.  This decrease in Tregs is similar to the decrease in total CD4+ T cell in the gut, and 
is associated with an increase in viral load and immune-activation.  While Treg function is 
altered in SIV infected macaques, Treg numbers and function are unchanged in sooty 
mangabeys, which do not progress towards an AIDS-like syndrome.  The conclusion thus far 
is that HIV and SIV replication is sensitive to Treg cell numbers and function, and a decrease 
in Tregs over the disease course contributes to overt immune hyperactivation.  Data from 
our lab shows that HIV infection of humanized mice leads to direct infection and depletion 
of Treg cells.  Our finding that HIV infection of Tregs is enhanced by FoxP3 expression 
supports a model in which preferential infection of Tregs and enhanced HIV-1 gene 
expression leads to an increase in Treg destruction, leading to loss of T cell activation 
control and thus an increase in activated T cell targets, allowing for further HIV replication.  
The Treg might very well be the key to disease progression, the critical cell that acts as both 
a target and mediator of future targets, and therefore the implication that FoxP3 enhances 
HIV gene transcription is a crucial component in HIV-1 disease progression. 
     
Future Direction and Studies 
  
There are several obvious future studies and directions related to the enhancement 
of HIV replication by FoxP3.  At the smallest scale, it is still unknown if FoxP3 can directly 
bind the HIV-1 LTR.  As previously stated, ChIP analysis of myc-tagged FoxP3 on the LTR 
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demonstrates interaction of FoxP3 with the LTR, although ChIP assays utilizing transcription 
factor binding site mutants, or successive 5’ deletions of the LTR have been inconclusive 
thus far.  If FoxP3 directly binds the LTR independent of transcription factor-mediated 
recruitment, we would expect to find a putative forkhead binding site in the LTR.  Thus far, 
we have been unable to find a forkhead binding motif in the U3 region to support FoxP3 
binding.  Conversely, FoxP3 can be recruited to the LTR by transcription factor association.  
This model is supported by the finding that FoxP3 can directly bind NFAT and NF-κB to 
modulate gene expression.  Future studies utilizing ChIP assays to determine FoxP3 binding 
to the LTR in the presence or absence of NF-κB would resolve this question.  With respect to 
enhancement of NF-κB at the LTR, it would be of worth understanding the mechanism of 
enhanced binding to the LTR when FoxP3 is expressed.  FoxP3 by itself is unable in alter 
nuclear localization or retention of NF-κB, therefore it would be interesting to determine if 
FoxP3 is somehow able to modify NF-κB post-translationally.  One possible way to 
determine this would be to immunoprecipitate NF-κB and analyze specific Foxp3-mediated 
changes by mass spectrometry.  Alternatively, as discussed in chapter 2, the binding affinity 
of the NF-κB sites located at the LTR are greater than that of the NF-κB sites located at the 
IL-2 promoter.  The fact that FoxP3 regulation of IL-2 is critically NFAT-dependent, the NF-κB 
activity is most likely LTR-specific due to the fact that the LTR is highly NF-κB-dependent. 
 On a much broader scale, it is currently unknown the effect of HIV infection on Treg 
function.  In SIV infection in vivo, the suppressive function of Treg cells is altered.  HIV 
infection of multiple cells types has been shown to alter cellular signaling and cytokine 
expression, therefore the next logical step would be to determine if infected Tregs are still 
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functional.  Does HIV-1 infection change Treg suppressive activity?  Can HIV infection alter 
cytokine expression, induce apoptosis, or other cellular activities?  If so, what are the viral 
gene products necessary for modulation of Treg function?   Answering these questions plus 
focusing on the role of Tregs in HIV disease progression will define future therapeutic 
targets to enhance retroviral therapy in patients.    
 
Chapter 3: FoxP3 inhibits HDAC1 activity to modulate gene expression  
 
Findings and Implications 
  
The third chapter expands upon the notion of FoxP3 as a regulator or transcription 
by describing a novel interaction between FoxP3 and the histone deacetylase HDAC1.  
Interest into the role of HDAC in FoxP3 regulation stemmed from the finding that FoxP3 
activation of HIV-1 LTR was insensitive to TSA.  TSA and other HDAC inhibitors have been 
shown to activate HIV-1 LTR a histone deacetylation-dependent mechanism.  Thus, FoxP3 
and HDACi are working through similar pathways to mediate transcription.  Therefore, the 
question of does FoxP3 work similar to HDACi was first determined by the overexpression of 
FoxP3 in Jurkat T cells and analysis of cellular HDAC activity.  We demonstrated that FoxP3 
expression was able to inhibit global HDAC activity, both upon overexpression of FoxP3 in 
Jurkat T cells and in naturally expressing primary Treg cells.  We then demonstrated that 
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FoxP3 inhibited HDAC1 specifically, that FoxP3 and HDAC1 interacted and co-fractionated in 
similar high molecular weight complexes by gel chromatography.  We also showed that 
knockdown of HDAC1 by shRNA inhibited both FoxP3-mediated regulation of HIV-1 LTR and 
IL-2 gene expression.   Finally, we demonstrated that IL-2 promoter activation in T cells 
requires HDAC1, and that HDAC1 is the likely target of HDACi-mediated IL-2 repression 
demonstrated in previous studies. 
 Class I and Class II HDACs play a versatile role in the regulation of cellular processes, 
including cell proliferation and survival (class I) and differentiation and maturation (class II).  
Thus, the use of inhibitors of HDACs (HDACi) has garnered attention for their potent 
anticancer activity, and increased levels of class I HDACs have been associated with a myriad 
of cancers (11).  Similarly, HDACi has been used in the treatment of graft rejection.  
Recently, the combination of HDACi and rapamycin (the latter a cell cycle inhibitor and 
potent immunosuppressive drug) administration decreased inflammatory bowel disease 
and induced permanent Treg-dependent islet and cardiac allograft survival and donor-
specific allograft tolerance in mice (12).  Mechanistically, HDACi was able to enhance in vivo 
Treg numbers and function, and was associated with increased FoxP3 expression and 
acetylation, along with increased inhibitory molecules GITR, PD-1, CTLA-4 and IL-10 in Tregs.  
Thus, the importance of inhibition of HDAC activity in the suppressive function of Treg cells 
is undeniable. 
 FoxP3 inhibition of HDAC1 has important implications in Treg biology and possibly 
clinical implications.  Until recently, the role of individual HDACs in the control of T cell 
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function and, more importantly, Treg function, was relatively understudied.  Within the last 
year, the Greene group demonstrated a role for HDAC7 in conjunction with Tip60 and FoxP3 
as a required complex in FoxP3-mediated IL-2 repression (13).  In HDAC9-/- mice, Treg 
suppressive function is increased and transduction of HDAC9-/- CD4+25- with Foxp3-
expressing retrovirus increased suppressive function compared to transduced wild type 
CD4+25- T cells.  Similarly, HDAC2-/- mice exhibited a 2-fold increase in Treg suppressive 
function (14).  The fact that FoxP3 acts as an HDAC inhibitor in this study gives support to 
the enhancement of Treg function by HDACi, and provides evidence for HDAC1 inhibition by 
HDACi as a target in in vivo enhancement of Treg function.  Thus it is clear multiple HDACs 
play a role in Treg biology, and until this study the role of HDAC1 in FoxP3-mediated 
promoter regulation was unknown.   
 
Future Directions and Studies 
  
The study of FoxP3 as an HDAC1-specific inhibitor is the first observation of this 
novel function for the FoxP3 protein.  The regulation of HDACs has been well documented, 
and a role for multi-subunit complex formation, post-translational modifications, and 
transcriptional regulation has been described in the literature.  We propose a mechanism 
wherein protein-protein interaction, and thus multimerization of FoxP3 and HDAC1, is 
required for FoxP3-mediated inhibition of HDAC1.  This is supported by the fact that point 
mutations inhibiting FoxP3 transcriptional regulatory function in Treg cells also ablates 
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FoxP3 inhibition of, and interaction with, HDAC1.  We cannot rule out other modifications 
to HDAC1, and future studies will be required to determine if FoxP3 is able to alter HDAC1 
by acetylation, phosphorylation, or other covalent modification.  We also did not describe 
the domain of HDAC1 necessary for Foxp3 interaction with HDAC1.  It will be important to 
map this interaction by deletion mutant mapping.  Li et al. showed that FoxP3 is acetylated 
by the HAT Tip60, and that this acetylation is required for FoxP3 function.  Does FoxP3 
inhibition of HDAC1 lead to an increase in Foxp3 acetylation?  This can be assessed by 
determining if knockdown of HDAC1 by shRNA is able to alter the acetylation status of 
FoxP3.  Finally, does HDAC1 knockdown inhibit Treg function?  Since HDAC1 knockout mice 
are embryonic lethal, conditional HDAC1 knockout mice could be used to assess Treg 
function.  Alternatively, efficient lentivirus delivery of shRNA specific for HDAC1 into 
primary Treg cells followed by in vitro Treg suppression assay would determine the role of 
HDAC1 in Treg function. 
 The question still remains as to what is the downstream target of FoxP3-mediated 
HDAC1 inhibition.  As stated above, FoxP3 inhibition of HDAC1 might lead to an increase in 
FoxP3 acetylation.  Since inhibition of HDACs is associated with upregulation of targeted 
promoters, it is unlikely that histones are a direct target for this function at promoters that 
are inhibited by FoxP3, such as the IL-2 promoter.  Rather, HDACs have also been known to 
acetylate non-histone targets such as transcription factors.  TSA treatment of T cells has 
been shown to alter NF-κB function.  Therefore it would be of interest to determine if 
FoxP3-mediated HDAC1 inhibition results in alteration of NF-κB function.  Studies looking at 
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the transactivation or DNA binding activity of NF-κB following FoxP3 expression and HDAC1 
knockdown will be of use. 
 
 
FoxP3 regulation of HIV-1 LTR expression.  FoxP3 enhancement of HIV LTR is associated with 
increased histone acetylation and NF-κB occupancy.  (1)  FoxP3 enhancement of NF-κB through p65 
modification (direct) or inhibition of NFAT1 binding (indirect).  (2) FoxP3 inhibition of HDAC1 results 
in increased acetylation of nuc-1 and enhanced gene expression. 
 
 
FoxP3 regulation of IL-2 gene expression.  FoxP3 enhancement of IL-2 is associated with decreased 
histone acetylation and no change in NF-κB occupancy.  Opposite of HIV-1 LTR, FoxP3 represses IL-2 
gene expression through inhibition of HDAC1 resulting in hyperacetylation of non-histone factors.  
Possible targets include NF-κB or NFAT.   
 
1 
2 
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Chapter 4: Foxp3 regulates IL-2 gene expression by inhibiting the ATPase chromatin 
remodeler Mi-2β. 
      
Finding and Implications 
 
 The hypothesis that FoxP3 is capable of regulating promoter activity through 
multiple mechanisms, from transcription factors to chromatin remodeling dynamics, 
broadened our scope to include such possibilities.  Work from other labs demonstrated that 
Treg cells have an ‘anergic-like’ dysfunction in vitro, characterized by inhibited in vitro 
cellular proliferation and suppressed cytokine activation.  Ultimately, it was demonstrated 
that the IL-2 promoter was functionally repressed by inhibition of chromatin accessibility or 
‘relaxation’ of the proximal promoter associated with TCR stimulation (15).  This supported 
the hypothesis of involvement of chromatin remodeling factors in both the normal 
activation of IL-2, but also a Treg-dependent function as well.  We initially chose to focus on 
FoxP3 recruitment of an inhibitory complex, the NuRD complex, as a potential mechanism 
of FoxP3-mediated repression.  In support of this hypothesis, FoxP3 fractionation by gel 
filtration demonstrated Foxp3 was found in high molecular fractions that included members 
of chromatin remodeling complexes, namely Brg-1 (SWI/SNF) and MBD3 (NuRD) (16).  We 
similarly showed that FoxP3 overexpressed in 293T cells co-fractionated with both HDAC1 
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and Mi-2β, thus we set out to describe the interaction of FoxP3 with Mi-2β.  We 
demonstrate that FoxP3 interacts with Mi-2β in Jurkat T cells and 293 cells, and this 
interaction requires the zinc finger domain of FoxP3.  We next determined the role of Mi-2β 
at the endogenous IL-2 promoter upon expression of FoxP3 by retroviral transduction.  
Interestingly, we showed that FoxP3 expression is associated with a loss of Mi-2β near the 
proximal promoter prior to stimulation and at multiple timepoints thereafter.  This did not 
occurring at a promoter known to be activated by FoxP3, the CD25 promoter.  We 
hypothesized that Mi-2β might be functioning as a positive regulator of IL-2 that is required 
for complete activation.  In support of this, we demonstrated knockdown of Mi-2β by 
shRNA inhibited PMA and Ionomycin activation of IL-2-luciferase reporter plasmid.  Thus, 
the conclusion for this study is that FoxP3 alters the binding of a chromatin remodeling 
factors to FoxP3-regulated promoters.  In this case, FoxP3 inhibits Mi-2β required for IL-2 
activation while potentially enhancing the CD25 promoter. 
 The NuRD complex is composed of several members that integrate chromatin 
remodeling with histone deacetylation.  Thus, this complex has been described as an 
inhibitor of promoter activity.  Support for the contrary came from a study showing that Mi-
2β in T cells is required for CD4 expression, therefore Mi-2β acts as a positive regulator of 
CD4 by recruiting p300 (HAT) to the promoter (17).  It is possible that Mi-2β could 
potentially recruit an activating complex to the IL-2 promoter as well.  The implication of 
this finding is that (i) there has yet to be described a ATP-dependent nucleosome 
remodeling factor required for IL-2 activation, and (ii) FoxP3 inhibition or association with a 
chromatin remodeling complex with ATP-dependent function has not been previously 
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described.  Importantly, through determination of the molecular interactions between 
FoxP3 and other cellular molecules, we are able to gain insight into the fundamental 
requirements for IL-2 activation following T cell stimulation.  From this study we can begin 
to determine other factors that are perhaps recruited to IL-2 or other promoters that are 
directly regulated by FoxP3.     
 
Future Directions and Studies        
 
 Little is known about the role of chromatin remodeling factors that regulate the 
nucleosome remodeling or histone acetylation and dynamics at the IL-2 promoter.  The HAT 
p300 has been shown to be recruited by factors and is required for proper IL-2 activation.  
Given the enhanced accessibility of the IL-2 promoter following TCR stimulation, there is a 
clear need for determining the ATPase-dependent chromatin remodelers that function at 
this and other promoters that respond to TCR signaling.  In Treg cells, FoxP3 is responsible 
for both the upregulation and downregulation of several genes.  The ability of FoxP3 to bind 
to and target these promoters suggests, along with data suggesting that FoxP3 is found with 
multiple chromatin remodeling complexes, that FoxP3 might recruit or displace factors 
differentially at promoters that are enhanced or repressed by FoxP3.  The most 
comprehensive way to determine the role of multiple ATP-dependent nucleosome 
remodelers and their role in FoxP3-dependent gene regulation would be to utilize a shRNA-
based microarray analysis.  Knocking down Mi-2β, Brg-1 or other ATP-dependent 
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nucleosome remodeling factors and determining the genes differentially expressed in the 
presence of FoxP3 would provide insight into the remodeling factors required for FoxP3-
mediated transcriptional regulation.   
 The requirement of Mi-2β for Treg function is also unknown.  Currently, we are 
unable to stably knockdown Mi-2β in Jurkat T cells.  Regardless, it will be of interest to 
determine if the knockdown of Mi-2β enhances Treg suppressive activity.  Conversely, if Mi-
2β is required for general IL-2 expression, does knockdown of Mi-2β in primary T cells 
inhibit IL-2 activation, possibly resulting in anergy induction?  Similarly, does the knockdown 
of Mi-2β lead to a similar inhibition of chromatin accessibility as described in murine Treg 
cells?  Answering these questions will give us a better understanding of the basic 
mechanisms of gene expression in T cells and mechanisms of FoxP3 regulation in Treg cells.      
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